Updated on 2024/11/02

写真a

 
TAKIZAWA Jun
 
Organization
Academic Assembly Institute of Medicine and Dentistry IGAKU KEIRETU Associate Professor
Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Homeostatic Regulation and Developments Associate Professor
Title
Associate Professor
External link

Degree

  • 博士(医学) ( 1997.3   新潟大学 )

Research Areas

  • Life Science / Hematology and medical oncology

Research History (researchmap)

  • 新潟大学医歯学総合病院   血液内科   病院教授

    2019.6

      More details

  • Niigata University   Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Homeostatic Regulation and Developments   Associate Professor

    2013.7

      More details

  • Niigata University   Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Cardiovascular and Vital Control   Assistant Professor

    2009.12 - 2013.6

      More details

  • Niigata University   Center for Transdisciplinary Research   Assistant Professor

    2008.1 - 2009.11

      More details

  • Niigata University   University Medical and Dental Hospital Bioscience Medical Research Center   Specially Appointed Assistant Professor

    2007.8 - 2007.12

      More details

Research History

  • Niigata University   Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Homeostatic Regulation and Developments   Associate Professor

    2013.7

  • Niigata University   Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Cardiovascular and Vital Control   Assistant Professor

    2009.12 - 2013.6

  • Niigata University   Center for Transdisciplinary Research   Assistant Professor

    2008.1 - 2009.11

  • Niigata University   University Medical and Dental Hospital Bioscience Medical Research Center   Specially Appointed Assistant Professor

    2007.8 - 2007.12

Education

  • Niigata University   Graduate School of Medicine

    1993.4 - 1997.3

      More details

    Country: Japan

    researchmap

  • Niigata University   Faculty of Medicine   School of Medicine

    1984.4 - 1990.3

      More details

    Country: Japan

    researchmap

Professional Memberships

▶ display all

Committee Memberships

  • 日本リンパ網内系学会   診療保険委員  

    2018   

      More details

  • 日本血液学会関東甲信越地方会   幹事  

    2017.3   

      More details

  • 日本血液学会   評議員  

    2015.9   

      More details

  • 日本リンパ網内系学会   評議員  

    2014   

      More details

 

Papers

  • Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study

    Jun Takizawa, Ritsuro Suzuki, Koji Izutsu, Toru Kiguchi, Hideki Asaoku, Yoshio Saburi, Taro Masunari, Atae Utsunomiya, Kengo Takeuchi, Naoya Nakamura, Koichi Ohshima, Michaela Gruber, Ulrich Jäger, Sadao Aoki, Junji Suzumiya

    International Journal of Hematology   119 ( 6 )   686 - 696   2024.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s12185-024-03741-z

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s12185-024-03741-z/fulltext.html

  • Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients. International journal

    Yasumasa Shimasaki, Hiroaki Miyoshi, Keisuke Kawamoto, Noriaki Yoshida, Tatsuzo Mishina, Kazutaka Nakashima, Teppei Imamoto, Takeshi Sugio, Eriko Yanagida, Takeharu Kato, Kyohei Yamada, Mai Takeuchi, Takaharu Suzuki, Mayuko Moritsubo, Takuya Furuta, Yoshitaka Imaizumi, Jun Takizawa, Koji Kato, Junji Suzumiya, Ritsuro Suzuki, Koichi Ohshima

    Cancer medicine   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes. METHODS: In this study, we compared the clinicopathological features of PTCL-NOS in a Japanese cohort, classified using an IHC algorithm. RESULTS: One hundred patients with PTCL-NOS were categorized as having PTCL-TBX21 (n = 55), PTCL-GATA3 (n = 24), or PTCL-unclassified (n = 21). When comparing PTCL-TBX21 and PTCL-GATA3, PTCL-TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity-related genes, such as PD-L1, LAG3, and IDO1, in PTCL-TBX21 than in PTCL-GATA3. PTCL-GATA3 had significantly worse overall survival (OS) than those with PTCL-TBX21 (p = 0.047), although a similar tendency was observed for progression-free survival (PFS) (p = 0.064). PTCL-GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09-3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93-4.61; p = 0.074). In the PFS analysis, PTCL-GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08-3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07-5.11; p = 0.032). CONCLUSION: The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.

    DOI: 10.1002/cam4.6793

    PubMed

    researchmap

  • 同種移植後day30の末梢血CD8TN、CD4TEM割合は急性GVHD発症のバイオマーカーとなる

    片桐 隆幸, 古山 悠里, 米沢 穂高, 諏訪部 達也, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血液学会学術集会   85回   880 - 880   2023.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 単一施設における節外性NK/T細胞リンパ腫、鼻腔(ENKL)における26例の後方視的解析 EBV-DNA定量の有用性

    山田 隆, 古山 悠里, 水戸部 正樹, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   85回   294 - 294   2023.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 当科におけるIVLBCL22例の後方視的解析

    鈴木 隆晴, 水戸部 正樹, 武田 ルイ, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 宮腰 淑子, 北嶋 俊樹, 小堺 貴司, 柴崎 康彦, 黒田 裕行, 棗田 学, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   85回   557 - 557   2023.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • CLL診断における塗抹標本上のSmudge細胞数の意義

    堀 健太郎, 山田 隆, 鈴木 隆晴, 曽根 博仁, 瀧澤 淳

    日本リンパ網内系学会会誌   63   142 - 142   2023.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • GB療法を施行した初発濾胞性リンパ腫17例の後方視的解析

    鈴木 隆晴, 水戸部 正樹, 山田 隆, 宮腰 淑子, 難波 亜矢子, 北嶋 俊樹, 大島 孝一, 黒田 裕行, 曽根 博仁, 瀧澤 淳

    日本リンパ網内系学会会誌   63   124 - 124   2023.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • ヘパプラスチンテストを取り入れた出血原因鑑別の検査戦略 後天性第V因子欠乏症における経験

    松田 将門, 山田 隆, 古山 悠里, 柴崎 康彦, 関 義信, 星山 良樹, 寺井 崇二, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血栓止血学会誌   34 ( 2 )   262 - 262   2023.5

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 単一施設における節外性NK/T細胞リンパ腫、鼻腔(ENKL)における26例の後方視的解析 EBV-DNA定量の有用性

    山田 隆, 古山 悠里, 水戸部 正樹, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   84回   294 - 294   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 当科におけるIVLBCL22例の後方視的解析

    鈴木 隆晴, 水戸部 正樹, 武田 ルイ, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 宮腰 淑子, 北嶋 俊樹, 小堺 貴司, 柴崎 康彦, 黒田 裕行, 棗田 学, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本血液学会学術集会   84回   557 - 557   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 同種移植後day30の末梢血CD8TN、CD4TEM割合は急性GVHD発症のバイオマーカーとなる

    片桐 隆幸, 古山 悠里, 米沢 穂高, 諏訪部 達也, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血液学会学術集会   84回   880 - 880   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. International journal

    Kana Miyazaki, Ritsuro Suzuki, Masahiko Oguchi, Senzo Taguchi, Jun Amaki, Takeshi Maeda, Nobuko Kubota, Dai Maruyama, Yasuhito Terui, Nodoka Sekiguchi, Jun Takizawa, Hiroyuki Tsukamoto, Tohru Murayama, Toshihiko Ando, Hiroshi Matsuoka, Masatoshi Hasegawa, Hideho Wada, Rika Sakai, Yoshihiro Kameoka, Norifumi Tsukamoto, Ilseung Choi, Yasufumi Masaki, Kazuyuki Shimada, Noriko Fukuhara, Takahiko Utsumi, Nobuhiko Uoshima, Yoshitoyo Kagami, Naoko Asano, Yasuo Ejima, Naoyuki Katayama, Motoko Yamaguchi

    Hematological oncology   40 ( 4 )   667 - 677   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with ENKTL diagnosed between 2000 and 2013 in a nationwide retrospective study in Japan were updated and analyzed. At a median follow-up of 8.4 years, the 5-year overall survival (OS) and progression-free survival (PFS) were 71% and 64%, respectively, in 140 localized ENKTL patients who received radiotherapy-dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) in clinical practice. Nine (6.4%) patients experienced second malignancies. In 155 localized ENKTL patients treated with RT-DeVIC, 10 (6.5%) experienced CNS relapse (median, 12.8 months after diagnosis). In five of them, the events were confined to the CNS. Nine of the 10 patients who experienced CNS relapse died within 1 year after CNS relapse. Multivariate analysis identified gingival (hazard ratio [HR], 54.35; 95% confidence interval [CI], 8.60-343.35) and paranasal involvement (HR, 7.42; 95% CI, 1.78-30.89) as independent risk factors for CNS relapse. In 80 advanced ENKTL patients, 18 received steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy as first-line treatment. Patients who received SMILE as their first-line treatment tended to have better OS than those who did not (p = 0.071). Six (7.5%) advanced ENKTL patients experienced isolated CNS relapse (median, 2.6 months after diagnosis) and died within 4 months of relapse. No second malignancies were documented in advanced ENKTL patients. In the entire cohort, the median OS after first relapse or progression was 4.6 months. 12 patients who survived 5 years after PFS events were disease-free at the last follow-up. Of those, 11 (92%) underwent hematopoietic stem cell transplantation. Our 8-year follow-up revealed the long-term efficacy and safety of RT-DeVIC and SMILE. The risk of CNS relapse is an important consideration in advanced ENKTL.

    DOI: 10.1002/hon.2977

    PubMed

    researchmap

  • イノツズマブによる再寛解導入に引き続いてブリナツモマブを投与し再移植できたB-ALLの1例

    米澤 穂高, 布施 香子, 水戸部 正樹, 武田 るい, 諏訪部 達也, 片桐 隆幸, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   62 ( 10 )   1526 - 1526   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • イノツズマブによる再寛解導入に引き続いてブリナツモマブを投与し再移植できたB-ALLの1例

    米澤 穂高, 布施 香子, 水戸部 正樹, 武田 るい, 諏訪部 達也, 片桐 隆幸, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   62 ( 10 )   1526 - 1526   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • AMLにおける造血幹細胞移植後1年未満の再発は高い死亡率と相関する(Post-transplant relapse of AML within one year is associated with a high mortality rate)

    片桐 隆幸, 本宮 奈津子, 武田 ルイ, 水戸部 正樹, 米沢 穂高, 諏訪部 達也, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    日本血液学会学術集会   83回   PS - 10   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma Reviewed International journal

    Yasuhito Terui, Shinya Rai, Koji Izutsu, Motoko Yamaguchi, Jun Takizawa, Junya Kuroda, Takayuki Ishikawa, Koji Kato, Youko Suehiro, Noriko Fukuhara, Ken Ohmine, Hideki Goto, Kazuhito Yamamoto, Nobuhiro Kanemura, Yasunori Ueda, Kenichi Ishizawa, Kyoya Kumagai, Atsuko Kawasaki, Tomohisa Saito, Misato Hashizume, Hirohiko Shibayama

    Cancer Science   112 ( 7 )   2845 - 2854   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2 , rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography-computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT.

    DOI: 10.1111/cas.14937

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.14937

  • 同種造血幹細胞移植後の慢性GVHDとしての類上皮肉芽腫および多発筋炎

    諏訪部 達也, 布施 香子, 水戸部 正樹, 武田 ルイ, 米沢 穂高, 片桐 隆幸, 河本 啓介, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 大島 孝一, 増子 正義

    臨床血液   62 ( 6 )   675 - 675   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 陰茎・陰嚢病変を合併した精巣原発DLBCL

    水戸部 正樹, 武田 ルイ, 米沢 穂高, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 6 )   668 - 668   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植後の慢性GVHDとしての類上皮肉芽腫および多発筋炎

    諏訪部 達也, 布施 香子, 水戸部 正樹, 武田 ルイ, 米沢 穂高, 片桐 隆幸, 河本 啓介, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 大島 孝一, 増子 正義

    臨床血液   62 ( 6 )   675 - 675   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 陰茎・陰嚢病変を合併した精巣原発DLBCL

    水戸部 正樹, 武田 ルイ, 米沢 穂高, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 6 )   668 - 668   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 乾燥人フィブリノゲン製剤の継続輸注で着床・妊娠継続・出産をし得た先天性低フィブリノゲン血症

    関 義信, 牛木 隆志, 増子 正義, 瀧澤 淳, 曽根 博仁, 奥村 伸生

    日本血栓止血学会誌   32 ( 2 )   214 - 214   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • GB療法施行中にHigh-grade B-cell lymphoma with MYC and BCL2 rearrangementsで再燃したFollicular lymphoma(Grade 3A)の2症例

    水戸部 正樹, 本宮 奈津子, 武田 ルイ, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本リンパ網内系学会会誌   61   114 - 114   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 腎障害を有する高悪性度B細胞リンパ腫症例にDA-EPOCH-Rを施行した1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 米沢 穂高, 田村 秀, 諏訪部 達也, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 5 )   532 - 532   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ルキソルチニブ・ヒドロキシウレア併用療法が奏効した慢性好中球性白血病(CNL)の1例

    武田 ルイ, 布施 香子, 片桐 隆幸, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 野本 信彦, 曽根 博仁, 増子 正義

    臨床血液   62 ( 5 )   529 - 530   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 乾燥人フィブリノゲン製剤の継続輸注で着床・妊娠継続・出産をし得た先天性低フィブリノゲン血症

    関 義信, 牛木 隆志, 増子 正義, 瀧澤 淳, 曽根 博仁, 奥村 伸生

    日本血栓止血学会誌   32 ( 2 )   214 - 214   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 腎障害を有する高悪性度B細胞リンパ腫症例にDA-EPOCH-Rを施行した1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 米沢 穂高, 田村 秀, 諏訪部 達也, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    臨床血液   62 ( 5 )   532 - 532   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ルキソルチニブ・ヒドロキシウレア併用療法が奏効した慢性好中球性白血病(CNL)の1例

    武田 ルイ, 布施 香子, 片桐 隆幸, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 野本 信彦, 曽根 博仁, 増子 正義

    臨床血液   62 ( 5 )   529 - 530   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • GB療法施行中にHigh-grade B-cell lymphoma with MYC and BCL2 rearrangementsで再燃したFollicular lymphoma(Grade 3A)の2症例

    水戸部 正樹, 本宮 奈津子, 武田 ルイ, 米沢 穂高, 鈴木 隆晴, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 柴崎 康彦, 増子 正義, 井上 佳菜子, 三好 寛明, 大島 孝一, 曽根 博仁, 瀧澤 淳

    日本リンパ網内系学会会誌   61   114 - 114   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia Reviewed

    Koji Izutsu, Tomohiro Kinoshita, Jun Takizawa, Suguru Fukuhara, Go Yamamoto, Yasuo Ohashi, Junji Suzumiya, Kensei Tobinai

    Japanese Journal of Clinical Oncology   51 ( 3 )   408 - 415   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    <title>Abstract</title>
    <sec>
    <title>Objective</title>
    Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is not approved for CLL. We investigated the efficacy and safety of FCR in this single-arm, multicenter study designed as a bridging study to the CLL8 study by the German CLL Study Group.


    </sec>
    <sec>
    <title>Methods</title>
    The study enrolled previously untreated patients with CLL of Binet stage B or C with active disease. Patients with a Cumulative Illness Rating Scale score of ≤6 and creatinine clearance of ≥70 ml/min were eligible. Patients received 6 cycles of FCR every 28 days and were followed for up to 1 year.


    </sec>
    <sec>
    <title>Results</title>
    Seven patients were enrolled. The best overall response rate according to the 1996 NCI-WG Guidelines, the primary endpoint of the study, was 71.4% (95% confidence interval, 29.0–96.3%), with one patient achieving complete response. No deaths or progression occurred during follow-up. The main adverse event was hematotoxicity. CD4-positive T-cell count decreased in all patients; most patients showed no reduction in serum immunoglobulin G.


    </sec>
    <sec>
    <title>Conclusion</title>
    Although the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-naïve fit Japanese patients with CD20-positive CLL.


    </sec>
    <sec>
    <title>Clinical trial number</title>
    JapicCTI-132285.


    </sec>

    DOI: 10.1093/jjco/hyaa215

    researchmap

  • Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma. International journal

    Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno

    Hematological oncology   39 ( 1 )   51 - 59   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiuxetan (90 Y-IT) after re-induction therapy with BR in patients with previously treated FL. This study included adult patients with relapsed FL who had undergone one or two prior therapies. Re-induction therapy with BR was administered every 4 weeks up to 4-6 cycles. If patients achieved at least partial response, 90 Y-IT was administered as consolidation therapy. The primary endpoint was 2-year progression-free survival (PFS) after consolidation. A total of 24 FL patients (median age 60 years) who had undergone one (n = 17) or two (n = 7) prior treatments received BR. After BR therapy, 22 patients proceeded to consolidation with 90 Y-IT, resulting in an overall 88% response rate to the protocol treatment. Within a median observation period of 46.8 months, the estimated 2-year PFS rate after the consolidation among the 22 patients receiving 90 Y-IT was 59% (95% confidence interval [CI], 38%-77%). Patients whose remission after previous treatment had lasted ≥2 years had a significantly higher 2-year PFS rate than patients whose remission after previous treatment had been <2 years (68% vs. 33%, Wilcoxon p = 0.0211). Major adverse events during the protocol treatment and within 2 years after the consolidation were hematological toxicities, but they were generally acceptable. Consequently, the estimated 2-year overall survival after the consolidation was 95% (95% CI, 74%-99%). In conclusion, in a subset of patients with previously treated FL, 90 Y-IT consolidation after BR re-induction conferred a durable remission, indicating that consolidation therapy using 90 Y-IT may be a novel therapeutic option for patients with relapsed FL (UMIN000008793).

    DOI: 10.1002/hon.2809

    PubMed

    researchmap

  • DA-EPOCH-R therapy for high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements in a patient with renal dysfunction Reviewed

    Masaki Mitobe, Keisuke Kawamoto, Takaharu Suzuki, Tatsuya Suwabe, Yasuhiko Shibasaki, Masayoshi Masuko, Kanako Inoue, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    Journal of Clinical and Experimental Hematopathology   61 ( 1 )   42 - 47   2021

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Lymphoreticular Tissue Research  

    High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive and safe regimens for patients with renal dysfunction are unknown. Herein, we report the successful use of DA-EPOCH-R therapy for double-hit lymphoma in a 64-year-old man with renal dysfunction. The patient had lymphoma-induced bilateral ureteral obstruction. Although renal dysfunction remained after removing the obstruction using R-CHOP therapy, we completed six cycles of DA-EPOCH-R therapy without any major adverse events. DA-EPOCH-R therapy may be a safe regimen for renal dysfunction patients.

    DOI: 10.3960/jslrt.20043

    PubMed

    researchmap

  • Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)

    Koji Izutsu, Junji Suzumiya, Jun Takizawa, Kenjiro Fukase, Maki Nakamura, Masahisa Jinushi, Hirokazu Nagai

    Journal of Clinical and Experimental Hematopathology   61 ( 3 )   135 - 144   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Lymphoreticular Tissue Research  

    Mantle cell lymphoma (MCL) accounts for approximately 3% of all cases of malignant lymphoma in Japan. The CLIMBER-DBR (Treatment practices and patient burden in chronic lymphocytic leukemia and mantle cell lymphoma patients in the real world: An observational database research in Japan) study examined the clinical characteristics, treatment patterns, and health-care resource utilization of MCL in a real-world clinical setting in Japan. Using the Japanese Medical Data Vision database, we extracted data for 1130 patients with MCL (ICD-10 code C83.1) registered between March 1, 2013 and February 28, 2018. The date of first MCL diagnosis was taken as the index date. The mean (standard deviation) age, body weight, and modified Charlson Comorbidity Index were 71.4 (10.9) years, 58.3 (11.7) kg, and 1.9 (1.6). respectively, and 24.6% were <= 65 years old. The median follow-up period was 654 days (first-third quartile 290.5-1049 days). A total of 802 patients (71.0%) underwent first-line treatment. The most common first-line treatment was bendamustine/rituximab (BR; 27.8%), followed by rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-CHOP; 15.6%) and rituximab/tetrahydropyranyl-adriamycin/cyclo-phosphamide/vincristine/prednisolone (R-THP-COP; 6.5%). The median (95% confidence interval) times to initial (first-line), second-line, and third-line treatments were 45 (36-62), 687 (624-734), and 1188 (1099-1444) days, respectively. Treatment practices for MCL in Japan are consistent with trends observed in Western countries. Our study can serve as a benchmark to assess future MCL treatments in Japan.

    DOI: 10.3960/jslrt.20056

    Web of Science

    researchmap

  • Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR)

    Jun Takizawa, Koji Izutsu, Hirokazu Nagai, Kenjiro Fukase, Maki Nakamura, Masahisa Jinushi, Junji Suzumiya

    Journal of Clinical and Experimental Hematopathology   61 ( 3 )   126 - 134   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Lymphoreticular Tissue Research  

    There are limited real-world data on the treatment practices and healthcare resource utilization associated with chronic lymphocytic leukemia (CLL) in Japan. In this study (CLIMBER-DBR), we performed retrospective analyses of the Japanese Medical Data Vision database, and extracted data for 2562 patients with newly diagnosed CLL (CLL-1 cohort) and 930 patients receiving CLL treatment (CLL-2 cohort) registered between March 1, 2013 and February 28, 2018. The median follow-up in the CLL-1 cohort was 721 (quartile 1-3: 363-1267) days and the median time to initial (first-line) treatment was 1331 (quartile 1-3: 189-not reached) days. In the CLL-2 cohort, the most frequently used regimens were fludarabine alone (17.7%), cyclophosphamide alone (13.7%), and bendamustine/rituximab (8.2%). The median (quartile 1-3) times to second-line and third-line treatments were 1066 (273-not reached) and 1795 (631-not reached) days, respectively. The CLIMBER-DBR was the first database research study to assess current treatment practices for CLL in Japan, where the treatment patterns were driven by the approval/reimbursement status of drugs in the study period. Our study provides an important benchmark for future studies of CLL in Japan.

    DOI: 10.3960/jslrt.20044

    Web of Science

    researchmap

  • Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma Reviewed International journal

    Ryo Kazama, Hiroaki Miyoshi, Mai Takeuchi, Kohta Miyawaki, Kazutaka Nakashima, Noriaki Yoshida, Keisuke Kawamoto, Eriko Yanagida, Kyohei Yamada, Takeshi Umeno, Takaharu Suzuki, Koji Kato, Jun Takizawa, Masao Seto, Koichi Akashi, Koichi Ohshima

    Cancer Science   111 ( 7 )   2608 - 2619   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    The interaction between CD47 and signal-regulatory protein-α (SIRPα) inhibits phagocytosis, thus affecting the clinical outcomes of neoplastic diseases. Although CD47 upregulation is associated with poor prognosis in several malignancies, the effect of SIRPα expression and its coexpression with CD47 remains unclear. This study aimed to investigate the clinicopathologic effect of CD47 and SIRPα expression in diffuse large B-cell lymphoma (DLBCL). Immunostaining of 120 biopsy samples showed that CD47 is primarily expressed in tumor cells, whereas SIRPα is expressed in nonneoplastic stromal cells, mostly macrophages. CD47high cases showed higher MYC protein expression and lower MYC translocation. The SIRPαhigh cases presented significantly shorter overall survival (OS) and progression-free survival (PFS) than SIRPαlow cases in the activated B-cell (ABC) subtype of DLBCL (P = .04 and P = .02, respectively). Both CD47high and SIRPαhigh presented significantly shorter OS and PFS than other cases among all DLBCL patients (P = .01 and P = .004, respectively), and the ABC type (P = .04 and P = .008, respectively) but not the germinal center B-cell type. Both CD47high and SIRPαhigh yielded a constant independent prognostic value for OS and PFS in multivariate analysis (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.20-7.43; P = .02; and HR, 2.87; 95% CI, 1.42-5.85; P = .003, respectively). To the best of our knowledge, this is the first study to report that combinatorial CD47 and SIRPα expression is a potential independent prognostic factor for DLBCL. Evaluation of CD47 and SIRPα expression could be useful before CD47 blockade therapy.

    DOI: 10.1111/cas.14437

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.14437

  • Langerhans細胞組織球症(LCH)患者に生じた皮膚肥満細胞症の1例

    武居 慎吾, 濱 菜摘, 岩井 由樹, 結城 明彦, 阿部 理一郎, 長崎 啓祐, 米沢 穂高, 瀧澤 淳, 梅津 哉, 柿田 明美

    日本皮膚科学会雑誌   130 ( 7 )   1662 - 1662   2020.6

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    researchmap

  • Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? Reviewed

    Junji Suzumiya, Jun Takizawa

    International Journal of Hematology   111 ( 5 )   642 - 656   2020.5

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s12185-020-02867-0

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s12185-020-02867-0/fulltext.html

  • Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial Reviewed International journal

    Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Masataka Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Tohru Izumi, Yoshihiro Kin, Kunihiro Tsukasaki, Daigo Hashimoto, Masaaki Yuge, Atsumi Yanagisawa, Yachiyo Kuwatsuka, Satoko Shimada, Yasufumi Masaki, Nozomi Niitsu, Hitoshi Kiyoi, Ritsuro Suzuki, Takashi Tokunaga, Shigeo Nakamura, Tomohiro Kinoshita

    The Lancet Oncology   21 ( 4 )   593 - 602   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. METHODS: PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan. Eligible patients had untreated histologically confirmed IVLBCL, were aged 20-79 years, had an Eastern Cooperative Group performance status of 0-3, and had no apparent CNS involvement at diagnosis. Patients received three cycles of R-CHOP (rituximab 375 mg/m2 intravenously on day 1 [except cycle one, which was on day 8]; cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2·0 mg] intravenously on day 1 of cycle one and day 2 of cycles two and three; and prednisolone 100 mg/day orally on days 1-5 of cycle one and days 2-6 of cycles two and three) followed by two cycles of rituximab with high-dose methotrexate (3·5 g/m2 intravenously on day 2 of cycles four and five) every 2 weeks and three additional cycles of R-CHOP. Intrathecal chemotherapy (methotrexate 15 mg, cytarabine 40 mg, and prednisolone 10 mg) was administered four times during the R-CHOP phase. The primary endpoint was 2-year progression-free survival. Efficacy analyses were done in all enrolled patients; safety analyses were done in all enrolled and treated patients. The trial is registered in the UMIN Clinical Trials Registry (UMIN000005707) and the Japan Registry of Clinical Trials (jRCTs041180165); the trial is ongoing for long-term follow-up. FINDINGS: Between June 16, 2011, and July 21, 2016, 38 patients were enrolled, of whom 37 were eligible; one patient was excluded because of a history of testicular lymphoma. Median follow-up was 3·9 years (IQR 2·5-5·5). 2-year progression-free survival was 76% (95% CI 58-87). The most frequent adverse events of grade 3-4 were neutropenia and leucocytopenia, which were reported in all 38 (100%) patients. Serious adverse events were hypokalaemia, febrile neutropenia with hypotension, hypertension, and intracerebral haemorrhage (reported in one [3%] patient each). No treatment-related deaths occurred during protocol treatment. INTERPRETATION: R-CHOP combined with rituximab and high-dose methotrexate plus intrathecal chemotherapy is a safe and active treatment for patients with IVLBCL without apparent CNS involvement at diagnosis, and this regimen warrants future investigation. FUNDING: The Japan Agency for Medical Research and Development, the Center for Supporting Hematology-Oncology Trials, and the National Cancer Center.

    DOI: 10.1016/s1470-2045(20)30059-0

    PubMed

    researchmap

  • Langerhans細胞組織球症(LCH)患者に生じた皮膚肥満細胞症の1例

    武居 慎吾, 濱 菜摘, 岩井 由樹, 結城 明彦, 阿部 理一郎, 長崎 啓祐, 米沢 穂高, 瀧澤 淳, 梅津 哉, 柿田 明美

    日本皮膚科学会雑誌   130 ( 3 )   419 - 419   2020.3

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    researchmap

  • Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. Reviewed International journal

    Takaharu Suzuki, Hiroaki Miyoshi, Joji Shimono, Keisuke Kawamoto, Fumiko Arakawa, Takuya Furuta, Kyohei Yamada, Eriko Yanagida, Mai Takeuchi, Masao Seto, Hirohito Sone, Jun Takizawa, Koichi Ohshima

    Pathology international   70 ( 5 )   280 - 286   2020.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Primary splenic low-grade B-cell lymphoma of the red pulp comprises hairy cell leukemia (HCL) and splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U). SPLL-U is a rare disease that includes subtypes of a hairy cell leukemia-variant (HCL-v), splenic diffuse red pulp small B-cell lymphoma (SDRPL) and other types that are known as narrow sense SPLL-U (SPLL-U-NS). Notably, limited information is available regarding the BRAF mutation (V600E) and cyclin D3 expression in subtypes of SPLL-U. Therefore, we performed a pathological analysis of the BRAF mutation (V600E) and characterized pathological features of SPLL-U. We reviewed the pathological findings of 12 SPLL-U cases. The 12 cases considered included two cases of HCL-v, six cases of SPLL-U-NS and four undetermined cases. The BRAF mutation (V600E) was detected in three cases, which were all SPLL-U-NS. Cases with the BRAF mutation (V600E) have increased levels of CD103 expression and decreased cyclin D3 and cyclin D1 expression compared with cases that lacked the BRAF mutation. These findings suggest that the BRAF mutation might play a significant role in SPLL-U. Therefore, the significance of the BRAF mutation should be evaluated via genomic or transcriptional analyses of a large cohort of SPLL-U patients.

    DOI: 10.1111/pin.12909

    PubMed

    researchmap

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   60 ( 10 )   1503 - 1503   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study Reviewed International journal

    Jun Ominato, Tokuhide Oyama, Hiroyuki Cho, Naoya Shiozaki, Hajime Umezu, Jun Takizawa, Takeo Fukuchi

    BMJ Open Ophthalmology   4 ( 1 )   e000295 - e000295   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BMJ  

    <sec><title>Objective</title>This study aimed to examine the natural course and relapse rate of IgG4-related ophthalmic disease (IgG4-ROD) after debulking surgery in Japanese patients.

    </sec><sec><title>Methods and analysis</title>This retrospective review included patients with IgG4-ROD who did not undergo further treatment following debulking surgery. The patients were diagnosed between January 2009 and December 2018 at the Department of Ophthalmology and Pathology, Niigata University Medical and Dental Hospital. The main outcome measures included postoperative IgG4-ROD recurrence rate and differences between patients with and without recurrent disease.

    </sec><sec><title>Results</title>Fifteen patients (six male, 9 female; 61.8±16.2 years) were included. Twelve patients (80.0%) had dacryoadenitis disease and three patients (20.0%) had orbital fat tissue disease. About 70%–100% of the lesion was resected in the debulking surgery and the pathological diagnosis was rendered. A definitive diagnosis was made in 13 cases (86.7%) and a probable diagnosis in 2 cases (13.3%). Patients were followed up for 39.0±25.5 months following operation. All patients had lesion volume reduction and patients with dacryoadenitis had eyelid swelling improvement after surgery. Two patients (13.3%) had disease recurrence and six patients (40.0%) had extraophthalmic lesions. There was no statistically significant difference in clinical features between relapsed and non-recurring cases.

    </sec><sec><title>Conclusion</title>We observed a 13.3% relapse rate following debulking surgery in patients with IgG4-ROD who did not undergo further treatment. This rate is lower than the documented relapse rate of 30%–70% following oral prednisolone therapy. Therefore, debulking surgery may be a treatment option for IgG4-ROD.

    </sec>

    DOI: 10.1136/bmjophth-2019-000295

    PubMed

    researchmap

  • Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Reviewed International journal

    Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N

    Annals of hematology   98 ( 7 )   1647 - 1655   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Extranodal NK/T cell lymphoma (NKTCL), nasal type (ENKL) that shows no apparent nasal involvement, is termed extranasal NKTCL or non-nasal NKTCL. In this study, we aimed to explore therapeutic approaches and outcomes in patients with extranasal NKTCL in current clinical practice. A data set of patients with newly diagnosed NKTCL who were diagnosed at 31 institutes in Japan between 2000 and 2013 was used for analysis. The patients' fitness for steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy was assessed using the major inclusion criteria of the SMILE phase 2 study. Of 358 patients, 47 (13%) had extranasal NKTCL. The most frequent extranodal sites of involvement in extranasal NKTCL were skin/subcutaneous tissue (n = 18). Six (13%) of the patients with extranasal NKTCL had localized disease and were diagnosed before 2010. With a median follow-up of 5.8 years, the 2-year overall survival (OS) in patients with nasal and extranasal NKTCL was 70% (95% confidence interval [CI], 65-75%) and 34% (95% CI, 21-47%), respectively. OS in patients with nasal NKTCL had a trend toward better according to treatment era (P = 0.063). In contrast, no obvious improvement of OS was observed in extranasal NKTCL (P = 0.43). The major inclusion criteria of the SMILE-P2 were met in 21% (10/47) of patients with extranasal NKTCL and 60% (188/311) of those with nasal NKTCL (P < 0.001). Despite the advent of new treatments for ENKL, OS remains unfavorable in extranasal NKTCL. A more effective therapy is needed for extranasal NKTCL.

    DOI: 10.1007/s00277-019-03689-9

    Scopus

    PubMed

    researchmap

    Other Link: http://orcid.org/0000-0002-5974-7614

  • Memory B cell pool of autoimmune pulmonary alveolar proteinosis patients contains higher frequency of GM-CSF autoreactive B cells than healthy subjects. Reviewed International journal

    Nei T, Urano S, Motoi N, Hashimoto A, Kitamura N, Tanaka T, Nakagaki K, Takizawa J, Kaneko C, Tazawa R, Nakata K

    Immunology Letters   212   22 - 29   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The IgG-type neutralizing GM-CSF autoantibody (GMAb) is known to be the causative agent for autoimmune pulmonary alveolar proteinosis (APAP). Previous studies report that serum levels of IgG-GMAb are approximately 50-fold higher in APAP patients than in healthy subjects (HS). Serum levels of IgM-GMAb are also higher in APAP patients than in HS, but this has been assumed to be an etiological bystander. However, the mechanism for the excessive production of IgG-GMAb in APAP remains unclear. To investigate this, we detected putative GMAb-producing B cells (PGMPB) by inoculated B cells from the peripheral blood of APAP patients, HS, and umbilical cord blood mononuclear cells (UCBMNs) with Epstein-Barr virus. Both ELISA and ELISPOT assays showed that IgM-type GMAb was consistently and frequently present in all three groups, whereas IgG-type GMAb was high only in APAP patients, in whom it was exclusively produced in memory B cells and not in naive B cells. Since PGMPB in UCBMNs produced IgM-GMAb, but not IgG-GMAb, to the same extent as in HS and APAP patients, most IgM-GMAb reacted with GM-CSF in a non-specific manner. The memory B cell pool of APAP patients contain higher frequency of PGMPB than that of healthy subjects.

    DOI: 10.1016/j.imlet.2019.05.013

    PubMed

    researchmap

  • Hodgkin lymphomaとAnaplastic large cell lymphomaの鑑別が困難であった巨大縦隔腫瘤を呈した1例

    河本 啓介, 鈴木 隆晴, 海發 茜, 田村 秀, 片桐 隆之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   59   133 - 133   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 日本では未分類である脾臓B細胞リンパ腫/白血病におけるBRAF遺伝子変異の分析(Analysis of BRAF mutation in splenic B-cell lymphoma/leukemia, unclassifiable in Japan)

    鈴木 隆晴, 三好 寛明, 河本 啓介, 荒川 文子, 古田 拓也, 下埜 城嗣, 山田 恭平, 柳田 恵理子, 瀬戸 加大, 曽根 博仁, 瀧澤 淳, 大島 孝一

    日本リンパ網内系学会会誌   59   145 - 145   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative. Reviewed International journal

    Kawamoto K, Suzuki T, Kasami T, Kiryu M, Sone H, Miyoshi H, Ohshima K, Takizawa J

    Hematological oncology   37 ( 2 )   212 - 214   2019.4

     More details

    Authorship:Last author   Language:English  

    DOI: 10.1002/hon.2565

    PubMed

    researchmap

  • Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Reviewed

    Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Tamura S, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

    Internal medicine (Tokyo, Japan)   58 ( 4 )   575 - 580   2019.2

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    A 61-year-old woman exhibited right inguinal lymphadenopathy and right lower limb edema approximately 1 month prior to hospitalization. She was diagnosed with high grade B-cell lymphoma, and a lymph node biopsy and fluorescence in situ hybridization indicated MYC, BCL2, and BCL6 rearrangements (triple-hit lymphoma). She had progressive disease that was CD20-negative after two courses of rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high-dose cytarabine (R-CODOX-M/IVAC) therapy. Subsequent etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (EPOCH) therapy was not effective. However, after two cycles of gemcitabine, dexamethasone, and cisplatin (GDP) therapy, she achieved a complete response and was able to undergo autologous peripheral blood stem cell transplantation. GDP therapy may be effective as salvage therapy for chemotherapy-resistant triple-hit lymphoma.

    DOI: 10.2169/internalmedicine.1686-18

    PubMed

    researchmap

  • Anaplastic large cell lymphoma, with 1,25(OH)<sub><sup>2</sup></sub>D<sub><sup>3</sup></sub>-mediated hypercalcemia: A case report. Reviewed

    Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J

    Journal of clinical and experimental hematopathology : JCEH   59 ( 1 )   22 - 28   2019

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    Hypercalcemia due to malignant tumors including malignant lymphomas is relatively common. Among cancer patients with hypercalcemia, humoral hypercalcemia of malignancy is the most common and accounts for about 80% of all cases with hypercalcemia. 1,25-dihydroxyvitamin D3(1,25(OH)2D3)-mediated hypercalcemia is relatively rare. Although malignant lymphoma has been also reported to cause 1,25(OH)2D3-mediated hypercalcemia, it is not known whether there is any association between 1,25(OH)2D3-mediated hypercalcemia and any specific histological type of malignant lymphoma. We herein report a case of an anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK) -negative with 1,25(OH)2D3-mediated hypercalcemia, which has never been previously reported. An 80-year-old Japanese man was admitted to our department due to acute exacerbation of hypercalcemia. He was diagnosed with ALCL, ALK-negative. Serum 1,25(OH)2D3 level was high and seemed to be associated with the lymphoma because the serum calcium and 1,25(OH)2D3 levels improved in response to chemotherapy. Histological findings showed that many CD68 positive macrophages were observed in the microenvironment of tumor cells. Lymphoma cells or tumor microenvironmental cells may produce 1,25(OH)2D3 because several previous reports showed the source of 1,25(OH)2D3 can be either lymphoma or tumor microenvironmental cells. Moreover, because 1,25(OH)2D3-mediated hypercalcemia has been reported regardless of the specific histological type of lymphoma, tumor microenvironmental cells may be involved in this condition. However, we could not identify the source of 1,25(OH)2D3 in this case. The association between 1,25(OH)2D3 production and prognosis in malignant lymphomas is yet unknown; further studies are needed to elucidate the clinical characteristics of malignant lymphoma with 1,25(OH)2D3-mediated hypercalcemia.

    DOI: 10.3960/jslrt.18033

    PubMed

    researchmap

  • Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. Reviewed

    Tamura S, Kawamoto K, Miyoshi H, Suzuki T, Katagiri T, Kasami T, Nemoto H, Miyakoshi S, Kobayashi H, Shibasaki Y, Masuko M, Takeuchi K, Ohshima K, Sone H, Takizawa J

    Journal of clinical and experimental hematopathology : JCEH   58 ( 4 )   161 - 165   2018.12

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Erdheim-Chester disease (ECD), a rare form of non-Langerhans cell histiocytosis, is characterized by the infiltration of foamy CD68+ and CD1a- histiocytes into multiple organ systems. Central nervous system (CNS) involvement has recently been reported to be a poor prognostic factor when treating ECD with interferon alpha. We report the case of a 66-year-old Japanese patient with ECD involving the CNS who harbored the BRAF V600E mutation and also concomitantly developed polycythemia vera with the JAK2 V617F mutation. We confirmed 2-chlorodeoxyadenosine (cladribine) therapy to be effective for the patient in this case.

    DOI: 10.3960/jslrt.18015

    PubMed

    researchmap

  • Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. Reviewed

    Itamura H, Ide M, Sato A, Sueoka-Aragane N, Sueoka E, Nishida A, Masunari T, Aoki S, Takizawa J, Suzumiya J, Kimura S

    International journal of hematology   108 ( 4 )   416 - 422   2018.10

  • 芽球性形質細胞様樹状細胞腫瘍におけるMYC異常 免疫芽球様細胞形態、薬剤感受性との関連(Recurrent MYC alteration in BPDCN: association with immunoblastoid morphology and drug response)

    坂本 佳奈, 片山 量平, 朝賀 礼美, 坂田 征士, 馬場 郷子, 仲宗根 秀樹, 小池 清恵, 津山 直子, 土橋 映仁, 佐々木 純, 一迫 玲, 高桑 恵美, 山崎 理絵, 瀧澤 淳, 前田 隆浩, 成田 美和子, 伊豆津 宏二, 神田 善伸, 大島 孝一, 竹内 賢吾

    臨床血液   59 ( 9 )   1503 - 1503   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. Reviewed International journal

    Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yasuji Kozai, Koji Kato, Masaharu Miyahara, Toshiaki Yujiri, Ilseung Choi, Katsumichi Fujimaki, Tsuyoshi Muta, Masaaki Kume, Sayaka Moriguchi, Shinobu Tamura, Takeharu Kato, Hiroyuki Tagawa, Junya Makiyama, Yuji Kanisawa, Yuya Sasaki, Daisuke Kurita, Kyohei Yamada, Joji Shimono, Hirohito Sone, Jun Takizawa, Masao Seto, Hiroshi Kimura, Koichi Ohshima

    Haematologica   103 ( 6 )   1018 - 1028   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 patients with adult-onset chronic active Epstein-Barr virus infection diagnosed between 2005 and 2015. Adult onset was defined as an estimated age of onset of 15 years or older. To characterize the clinical features of these adults, we compared them to those of 75 pediatric cases (estimated age of onset <15 years). We compared the prognosis of adult-onset chronic active Epstein-Barr virus infection with that of patients with nasal-type (n=37) and non-nasal-type (n=45) extranodal NK/T-cell lymphoma. The median estimated age of onset of these lymphomas was 39 years (range, 16-86 years). Compared to patients with pediatric-onset disease, those in whom the chronic active Epstein-Barr virus infection developed in adulthood had a significantly decreased incidence of fever (P=0.005), but greater frequency of skin lesions (P<0.001). Moreover, hypersensitivity to mosquito bites and the occurrence of hydroa vacciniforme were less frequent in patients with adult-onset disease (P<0.001 and P=0.0238, respectively). Thrombocytopenia, high Epstein-Barr virus nuclear antigen antibody titer, and the presence of hemophagocytic syndrome were associated with a poor prognosis (P=0.0087, P=0.0236, and P=0.0149, respectively). Allogeneic hematopoietic stem cell transplantation may improve survival (P=0.0289). Compared to pediatric-onset chronic active Epstein-Barr virus infection and extranodal NK/T-cell lymphoma, adult-onset chronic active Epstein-Barr virus infection had a poorer prognosis (P<0.001 and P=0.0484, respectively). Chronic active Epstein-Barr virus infection can develop in a wide age range, with clinical differences between adult-onset and pediatric-onset disease. Adult-onset chronic active Epstein-Barr virus infection is a disease with a poor prognosis. Further research will be needed.

    DOI: 10.3324/haematol.2017.174177

    PubMed

    researchmap

  • Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response Reviewed International journal

    Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K

    Leukemia   32 ( 12 )   2590 - 2603   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare skin-tropic hematological malignancy of uncertain pathogenesis and poor prognosis. We examined 118 BPDCN cases for cytomorphology, MYC locus rearrangement, and MYC expression. Sixty-two (53%) and 41 (35%) cases showed the classic and immunoblastoid cytomorphology, respectively. Forty-one (38%) MYC+BPDCN (positive for rearrangement and expression) and 59 (54%) MYC-BPDCN (both negative) cases were identified. Immunoblastoid cytomorphology was significantly associated with MYC+BPDCN. All examined MYC+BPDCNs were negative for MYB/MYBL1 rearrangement (0/36). Clinically, MYC+BPDCN showed older onset, poorer outcome, and localized skin tumors more commonly than MYC-BPDCN. MYC was demonstrated by expression profiling as one of the clearest discriminators between CAL-1 (MYC+BPDCN) and PMDC05 (MYC-BPDCN) cell lines, and its shRNA knockdown suppressed CAL-1 viability. Inhibitors for bromodomain and extra-terminal protein (BETis), and aurora kinases (AKis) inhibited CAL-1 growth more effectively than PMDC05. We further showed that a BCL2 inhibitor was effective in both CAL-1 and PMDC05, indicating that this inhibitor can be used to treat MYC-BPDCN, to which BETis and AKis are probably less effective. Our data will provide a rationale for the development of new treatment strategies for patients with BPDCN, in accordance with precision medicine.

    DOI: 10.1038/s41375-018-0154-5

    PubMed

    researchmap

  • GDP療法がtriple-hit lymphomaの救援療法として有効であった1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 田村 秀, 小堺 貴司, 難波 亜矢子, 諏訪部 達也, 笠見 卓哉, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 5 )   620 - 621   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Reviewed International journal

    Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K

    Hematol Oncol.   36 ( 3 )   591 - 599   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Myeloid sarcoma (MS) is a rare condition and is an extramedullary tumour of immature myeloid cells. It is now known that the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway suppresses the host antitumor responses and that these products are expressed on both tumour cells and tumour-infiltrating cells in various malignancies. However, little is known about the significance of PD-1/PD-L1 expression on tumour cells and tumour microenvironmental cells in MS. To investigate the clinicopathological significance of PD-1/PD-L1 expression in MS, we analyzed 98 patients by immunohistochemistry. Of these, 10.2% of cases had neoplastic tumour cells positive for PD-L1 (nPD-L1+ ). However, the rate of nPD-L1+ was <5% (range: 0.27 to 2.97%). On the other hand, PD-L1 expression on 1 or more of stromal cells in the tumour microenvironment (miPD-L1+ ) was observed in 37.8% of cases. Because all nPD-L1+ cases expressed PD-1 on less than 5% of tumour cells, we compared the miPD-L1+ and miPD-L1- groups. There was a correlation between miPD-L1+ status and the number of PD-1-expressing tumour -infiltrating lymphocytes (PD-1+ TILs; P = .0229). miPD-L1+ was found to be associated with poorer overall survival and progression-free survival (P = .00392, P = .00261, respectively). Multivariate analysis also confirmed miPD-L1+ to be an independent poor prognostic factor. In conclusion, our study indicated that the immunotherapy blocking the PD-1/PD-L1 pathway may improve the clinical outcome of MS.

    DOI: 10.1002/hon.2506

    PubMed

    researchmap

  • MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia. Reviewed

    Kozakai T, Takahashi M, Higuchi M, Hara T, Saito K, Tanaka Y, Masuko M, Takizawa J, Sone H, Fujii M

    International journal of hematology   107 ( 3 )   337 - 344   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Membrane-associated guanylate kinase with inverted orientation protein 1 (MAGI-1) is a cytoplasmic scaffold protein that interacts with various signaling molecules; it negatively controls the cell growth of various types of cells and positively controls cell-cell interaction. In T cells, MAGI-1 has been shown to inhibit Akt activity through its interaction with PTEN and MEK1. In this study we found that MAGI-1 expression is decreased in multiple (9 out of 15) human T-cell leukemia cell lines, including adult T-cell leukemia (ATL), T-cell acute lymphoblastic leukemia and chronic T-cell lymphocytic leukemia. The overexpression of MAGI-1 protein in a MAGI-1-low ATL cell line reduced cellular growth. While the overexpression of MAGI-1 protein in a MAGI-1-low ATL cell line reduced the Akt and MEK activities, the knockdown of MAGI-1 in a MAGI-1-high ATL cell line augmented the Akt and MEK activities. Collectively, the findings of the present study suggest that the decreased expression of MAGI-1 in human T cells contributes to the development of several types of T-cell leukemia, partly through the stimulation of the Akt and MEK pathways.

    DOI: 10.1007/s12185-017-2359-1

    PubMed

    researchmap

  • Clinicopathological and genomic analysis of double-hit follicular lymphoma: Comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Reviewed

    Masashi Miyaoka, Yara Y. Kikuti, Joaquim Carreras, Haruka Ikoma, Shinichiro Hiraiwa, Akifumi Ichiki, Minoru Kojima, Kiyoshi Ando, Tomoyuki Yokose, Rika Sakai, Masahiro Hoshikawa, Naoto Tomita, Ikuo Miura, Katsuyoshi Takata, Tadashi Yoshino, Jun Takizawa, Silvia Bea, Elias Campo, Naoya Nakamura

    Modern Pathology   31 ( 2 )   313 - 326   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nature Publishing Group  

    Most high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are aggressive B-cell lymphomas. Occasional double-hit follicular lymphomas have been described but the clinicopathological features of these tumors are not well known. To clarify the characteristics of double-hit follicular lymphomas, we analyzed 10 cases of double-hit follicular lymphomas and 15 cases of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements for clinicopathological and genome-wide copy-number alterations and copy-neutral loss-of-heterozygosity profiles. For double-hit follicular lymphomas, the median age was 67.5 years (range: 48-82 years). The female/male ratio was 2.3. Eight patients presented with advanced clinical stage. The median follow-up time was 20 months (range: 1-132 months). At the end of the follow-up, 8 patients were alive, 2 patients were dead including 1 patient with diffuse large B-cell lymphoma transformation. Rearrangements of MYC/BCL2, MYC/BCL6, and MYC/BCL2/BCL6 were seen in 8, 1, and 1 cases, respectively. The partner of MYC was IGH in 6 cases. There were no cases of histological grade 1, 4 cases of grade 2, 5 cases of grade 3a, and 1 case of grade 3b. Two cases of grade 3a exhibited immunoblast-like morphology. Immunohistochemistry demonstrated 9 cases with ≥50% MYC-positive cells. There was significant difference in MYC intensity (P=0.00004) and MIB-1 positivity (P=0.001) between double-hit follicular lymphomas and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. The genome profile of double-hit follicular lymphomas was comparable with conventional follicular lymphomas (GSE67385, n=198) with characteristic gains of 2p25.3-p11.1, 7p22.3-q36.3, 12q11-q24.33, and loss of 18q21.32-q23 (Po0.05). In comparison with highgrade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements, double-hit follicular lymphomas had fewer copy-number alterations and minimal common region of gain at 2p16.1 (70%), locus also significant against conventional follicular lymphomas (P=0.0001). In summary, double-hit follicular lymphomas tended to be high-grade histology, high MYC protein expression, high MYC/IGH fusion, and minimal common region of gain at 2p16.1. Double-hit follicular lymphomas seemed to be a different disease from high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements and have an indolent clinical behavior similar to follicular lymphomas without MYC rearrangement.

    DOI: 10.1038/modpathol.2017.134

    Scopus

    PubMed

    researchmap

  • Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Reviewed International journal

    Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa

    Hematological oncology   36 ( 1 )   166 - 173   2018.2

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma. However, the efficacy of BV toward ENKTL has not yet been established. Therefore, we investigated the expression of CD30 in a large cohort to evaluate BV as a potential treatment for ENKTL. In this study, 97 Japanese patients with newly diagnosed ENKTL between January 2007 and December 2015 were enrolled. Flow cytometry and immunohistochemistry were performed for the evaluation of CD30 expression. If the cut-off value of CD30 expression is 1% or more, there were 55 positive cases (56.5%). According to the localization of lesion, the frequency of CD30 expression was significantly higher in the non-nasal type than in the nasal type (P = .0394). No differences were observed in almost all clinical characteristics between CD30-positive cases and CD30-negative cases. In addition, the expression of CD30 was not a prognostic factor for either overall survival or progression-free survival. In conclusion, frequent expression of CD30 in ENKTL suggests anti-CD30 antibody-based therapy may be an effective treatment.

    DOI: 10.1002/hon.2482

    PubMed

    researchmap

  • Improved Prognosis of Extranodal NK/T-Cell Lymphoma, Nasal Type (ENKL) of Nasal Origin but Not Extranasal Origin: An Analysis of NKEA Study Reviewed

    Yamaguchi Motoko, Suzuki Ritsuro, Miyazaki Kana, Amaki Jun, Takizawa Jun, Sekiguchi Nodoka, Inagaki Shiori, Tomita Naoto, Wada Hideho, Kobayashi Yukio, Niitsu Nozomi, Ando Toshihiko, Maeda Takeshi, Saito Bungo, Matsuoka Hiroshi, Sakai Rika, Kubota Nobuko, Masaki Yasufumi, Asano Naoko, Oguchi Masahiko, Katayama Naoyuki

    BLOOD   130   2017.12

  • 抗原特異的細胞傷害性T細胞(CTL)の増幅と機能の検討

    小川 彩空, 増子 正義, 後藤 若奈, 内山 孝由, 橋本 誠雄, 柴崎 康彦, 瀧澤 淳, 成田 美和子

    日臨技北日本支部医学検査学会抄録集   6回   128 - 128   2017.10

     More details

    Language:Japanese   Publisher:日臨技北日本支部医学検査学会  

    researchmap

  • Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome A case report and literature review Reviewed

    Takayuki Katagiri, Takashi Ushiki, Masayoshi Masuko, Tomoyuki Tanaka, Shukuko Miyakoshi, Kyoko Fuse, Yasuhiko Shibasaki, Jun Takizawa, Sadao Aoki, Hirohito Sone

    MEDICINE   96 ( 36 )   e7975   2017.9

     More details

    Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Rationale: Myeloid sarcoma (MS) and leukemia cutis (LC) are extramedullary tumors comprising myeloid blasts. They can occur de novo or concurrently with hematological disorders, usually acute myeloid leukemia (AML). AML chemotherapy is generally the initial therapy for MS and LC, and hematopoietic stem cell transplantation (HSCT) can be considered as additional therapy. However, treatment for older patients who are unable to continue intensive chemotherapy is not currently standardized.
    Patientconcerns: A 71-year-old Japanese woman was diagnosed with multiple MSs associated with myelodysplastic syndrome (MDS), using bone marrow aspiration and lymph node biopsy.
    Diagnoses: Additionally, LC was diagnosed by skin biopsy. Extramedullary MS and LC lesions were formed by massive infiltration of myeloblastic cells.
    Interventions: Twenty courses of 5-azacytidine (5-Aza) were administrated as maintenance therapy after induction therapy with daunorubicin and cytarabine.
    Outcomes: Myeloblasts decreased in the bone marrow and the LC disappeared after induction therapy. The MSs completely disappeared, except for the palatine tonsil lesion, after 5-Aza maintenance therapy. 5-Aza treatment provided long-term partial response for more than 21 months.
    Lessons: 5-Aza was well tolerated and may be a good option for the treatment of MS and LC associated with MDS, especially in older patients who cannot receive HSCT.

    DOI: 10.1097/MD.0000000000007975

    Web of Science

    PubMed

    researchmap

  • Clinicopathological features of cryptococcal lymphadenitis and a review of literature. Reviewed

    Kawamoto K, Miyoshi H, Suzuki T, Muto R, Yamada K, Yanagida E, Koshino M, Sasaki Y, Takizawa J, Sone H, Sugita Y, Seto M, Ohshima K

    Journal of clinical and experimental hematopathology : JCEH   57 ( 1 )   26 - 30   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cryptococcosis is an invasive fungal infection in immunocompromised patients. The clinicopathological characteristics of cryptococcal lymphadenitis are not well known. We analyzed three cases of cryptococcal lymphadenitis and compared their characteristics with those in previous reports. Two patients were human immunodeficiency virus (HIV) carriers, and one patient was a human T-cell leukemia virus type-1 (HTLV-1) carrier. The age of the HTLV-1 carrier with cryptococcosis was much higher than that of the HIV-1 carriers. CD4-positive cell counts in peripheral blood were 5.8/μL (Case 1) and 79.9/μL (Case 2) in the HIV carriers and 3285/μL in the HTLV-1 carrier (Case 3). According to flow cytometric analysis of the lymph nodes of Cases 1, 2, and 3, 50.0%, 87.1%, and 85.9%, respectively, of the T-cells were CD3; 9.8%, 16.3%, and 75.8%, respectively, were CD4; and 35.5%, 77.3%, and 10.2%, respectively, were CD8. Cryptococcus neoformans was detected in tissue culture in all patients. Although gelatinous lesions and numerous fungal cocci were observed in the two HIV patients, the granuloma formation was small. Gelatinous formation and granuloma formation were observed in the HTLV-1 carrier. Necrosis was observed in all cases. In previous reports, granuloma formation, epithelioid cells, and necrotic lesions were observed in most cases. Most of the patients were also immunosuppressed. However, no HTLV-1 carrier was detected. In conclusion, lymphadenopathy in a HTLV-1 carrier may suggest the presence of cryptococcal lymphadenitis. The frequency of cryptococcosis in HTVL-1 carriers may increase with increase in the long-term survival rate of HTLV-1 carriers.

    DOI: 10.3960/jslrt.17011

    PubMed

    researchmap

  • Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified Reviewed

    Keisuke Kawamoto, Hiroaki Miyoshi, Eriko Yanagida, Noriaki Yoshida, Junichi Kiyasu, Yasuji Kozai, Tatsuma Morikita, Takeharu Kato, Hitoshi Suzushima, Shinobu Tamura, Tsuyoshi Muta, Koji Kato, Tetsuya Eto, Ritsuko Seki, Koji Nagafuji, Hirohito Sone, Jun Takizawa, Masao Seto, Koichi Ohshima

    EUROPEAN JOURNAL OF HAEMATOLOGY   98 ( 5 )   459 - 466   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    ObjectivesT-cell prolymphocytic leukemia (T-PLL) is a very rare, aggressive T-cell neoplasm. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is also a highly aggressive lymphoma. These two diseases can often be confused with each other; therefore, we aimed to determine the clinical and pathological differences between T-PLL and PTCL-NOS.
    MethodsWe analyzed 15 T-PLL and 91 PTCL-NOS patients and also compared clinical features between T-PLL and PTCL-NOS with leukemic presentation. Peripheral blood images and biopsy specimens were analyzed, and treatment responses were determined via imaging modalities. The clinicopathological characteristics were statistically compared.
    ResultsT-PLL cells were smaller in size than those of PTCL-NOS with leukemic presentation (P=.0068); moreover, PTCL-NOS cells with leukemic presentation were smaller than those of PTCL-NOS without leukemic presentation (P=.0017). Immunophenotypic patterns in T-PLL and PTCL-NOS were similar. Five-year overall survival rates of T-PLL and all PTCL-NOS patients were 57.5% and 36.8%, respectively. No significant differences were found in clinical manifestations or prognoses; T-PLL and PTCL-NOS with leukemic presentation had essentially equivalent characteristics.
    ConclusionT-PLL and PTCL-NOS may share common biological and clinical characteristics in Japanese patients.

    DOI: 10.1111/ejh.12856

    Web of Science

    PubMed

    researchmap

  • Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan Reviewed

    Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi, Naoko Asano, Jun Amaki, Takeshi Akiba, Takeshi Maeda, Satoshi Itasaka, Nobuko Kubota, Yoshihiro Saito, Yukio Kobayashi, Jun Itami, Kyoko Ueda, Kana Miyazaki, Noriko Ii, Naoto Tomita, Nodoka Sekiguchi, Jun Takizawa, Bungo Saito, Tohru Murayama, Toshihiko Ando, Hideho Wada, Rie Hyo, Yasuo Ejima, Masatoshi Hasegawa, Naoyuki Katayama

    JOURNAL OF CLINICAL ONCOLOGY   35 ( 1 )   32 - +   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Purpose
    To elucidate the management and outcomes of patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL), who were diagnosed between 2000 and 2013 in Japan.
    Patients and Methods
    Data from 358 patients with ENKL diagnosed between 2000 and 2013 from 31 institutes were retrospectively analyzed.
    Results
    Patients' median age was 58 years, and 257 (72%) had localized disease. The most common first-line treatment was radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) (66%) for localized ENKL and L-asparaginase-containing chemotherapy (30%) for advanced ENKL. With a median follow-up of 5.8 years, overall survival (OS) rates at 5 years for localized and advanced ENKL were 68% and 24%, respectively. The prognostic index of natural killer lymphoma was validated in our study, although only 4% of patients with localized ENKL were classified as high risk. With a median follow-up of 5.6 years, OS and progression-free survival at 5 years in the 150 patients who received RT-DeVIC in clinical practice were 72% (95% CI, 63% to 78%) and 61% (95% CI, 52% to 69%), respectively. Toxicities of RT-DeVIC were comparable to those in a previous trial. Multivariate analysis in patients with localized ENKL who received RT-DeVIC identified elevated soluble interleukin-2 receptor as an independent predictive factor for worse OS and progression-free survival (adjusted hazard ratios, 2.28 and 2.46; 95% CI, 1.24 to 4.23 and 1.42 to 4.28; P = .008 and .0014, respectively).
    Conclusion
    Favorable OS in response to new treatments was demonstrated in a large number of patients. Improved treatment approaches are needed for localized ENKL exhibiting elevated pretreatment soluble interleukin-2 receptor. (C) 2016 by American Society of Clinical Oncology

    DOI: 10.1200/JCO.2016.68.1619

    Web of Science

    PubMed

    researchmap

  • A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Reviewed

    Katsuhiro Miura, Jun Konishi, Takaaki Miyake, Masanori Makita, Atsuko Hojo, Yasufumi Masaki, Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiya, Koichi Kitazume, Yoshinobu Maeda, Jun Takizawa, Rika Sakai, Tomofumi Yano, Kazuhiko Yamamoto, Kazutaka Sunami, Yasushi Hiramatsu, Kazutoshi Aoyama, Hideki Tsujimura, Jun Murakami, Yoshihiro Hatta, Masatoshi Kanno

    ONCOLOGIST   22 ( 5 )   554 - 560   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Background. Decision-making models for elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are in great demand.
    Patients and Methods. The Society of Lymphoma Treatment in Japan (SoLT-J), in collaboration with the West-Japan Hematology and Oncology Group (West-JHOG), collected and retrospectively analyzed the clinical records of &gt;= 65-year-old patients with DLBCL treated with R-CHOP from 19 sites across Japan to build an algorithm that can stratify adherence to R-CHOP.
    Results. A total of 836 patients with a median age of 74 years ( range, 65-96 years) were analyzed. In the SoLT-J cohort (n=555), age &gt;75 years, serum albumin level &lt;3.7 g/dL, and Charlson Comorbidity Index score &gt;= 3 were independent adverse risk factors and were defined as the Age, Comorbidities, and Albumin (ACA) index. Based on their ACA index score, patients were categorized into "excellent" (0 points), "good" (1 point), "moderate" (2 points), and "poor" (3 points) groups. This grouping effectively discriminated the 3-year overall survival rates, mean relative total doses (or relative dose intensity) of anthracycline and cyclophosphamide, unanticipated R-CHOP discontinuance rates, febrile neutropenia rates, and treatment-related death rates. Additionally, the ACA index showed comparable results for these clinical parameters when it was applied to the West-JHOG cohort (n5281).
    Conclusion. The ACA index has the ability to stratify the prognosis, tolerability to cytotoxic drugs, and adherence to treatment of elderly patients with DLBCL treated with R-CHOP.

    DOI: 10.1634/theoncologist.2016-0260

    Web of Science

    PubMed

    researchmap

  • Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy. Reviewed

    Suwabe T, Shibasaki Y, Kaihatsu A, Katagiri T, Miyakoshi S, Fuse K, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 1 )   32 - 36   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 62-year-old man with CHOP refractory adult T-cell leukemia/lymphoma (ATLL) received anti-CC chemokine receptor 4 antibody (mogamulizumab) combined with CHOP and achieved complete remission. At 71 days after the final administration of mogamulizumab, he received umbilical cord blood transplantation (CBT) using reduced intensity conditioning. Umbilical cord blood engraftment was confirmed on day16. Grade II acute graft-versus-host disease (GVHD) was diagnosed on day60 and was controlled by administration of methylprednisolone. There was no evidence of relapse at 9 months after CBT. Ratios of regulatory T cells in CD4 positive T cells were remarkably low during all of these periods. Since mogamulizumab reduces regulatory T cells, the frequency and severity of acute GVHD were reported to be increased in patients administered mogamulizumab before allogenic stem cell transplantation. Further experiences are needed for selecting optimal donor sources, the portability period and GVHD prophylaxis for patients using mogamulizumab before allogeneic stem cell transplantation.

    DOI: 10.11406/rinketsu.58.32

    PubMed

    researchmap

  • [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity]. Reviewed

    Tanaka T, Kozakai T, Kitajima T, Fuse K, Kobayashi H, Ushiki T, Shibazaki Y, Moriyama M, Takizawa J, Sone H, Fuse I, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 12 )   2402 - 2405   2017

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>A 75-year-old woman suffered a cat bite 10 months after myelodysplastic syndrome (MDS) diagnosis. She visited our hospital because the internal bleeding of the wound did not improve. Although the wound was treated, the bleeding did not stop. She was hospitalized for emergency medical treatment because the bleeding volume exceeded 200 m<i>l</i>. Although her platelet count was normal, the platelet function test showed a decrease in collagen and arachidonic acid aggregation. After platelet transfusion, her bleeding stopped. Patients with MDS may potentially have platelet dysfunction. In the case of bleeding without thrombocytopenia, a platelet function test should be performed and treatment intervention, such as platelet transfusion, should be considered.</p>

    DOI: 10.11406/rinketsu.58.2402

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2018121562

  • Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. Reviewed

    Suzuki T, Kawamoto K, Tamura S, Uemura S, Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y, Moriyama M, Masuko M, Narita M, Sone H, Aoki S, Nakamura N, Oshima K, Takizawa J

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 8 )   905 - 911   2017

     More details

    Authorship:Last author, Corresponding author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    We retrospectively analyzed clinical and pathological features, treatments, and prognoses in 28 patients with newly diagnosed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in Niigata University Medical and Dental Hospital. Of them, 16 were males and 12 were females, and their median age was 62.5 (range, 26-88) years. The International Prognostic Index was high-intermediate/high in 68% of patients. Twelve patients were treated with CHOP/THP-COP and nine with third-generation chemotherapy regimens. At a median follow-up period of 30 (range: 1-164) months, the 2-year overall survival and progression-free survival rates were 61% and 44%, respectively. Further investigation of novel agents for treating PTCL-NOS is warranted.

    DOI: 10.11406/rinketsu.58.905

    PubMed

    researchmap

  • The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma Reviewed

    Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa

    LEUKEMIA & LYMPHOMA   57 ( 12 )   2763 - 2770   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:TAYLOR & FRANCIS LTD  

    We previously developed a prognostic index, SIL, which includes advanced stage (5), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p &lt; 0.0001). When the patients were divided by age (&lt;= 60 years and &gt;60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and &gt;1). The SIL index is a simple and objective prognostic indicator in DLBCL.

    DOI: 10.1080/10428194.2016.1195498

    Web of Science

    PubMed

    researchmap

  • Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients Reviewed

    Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Jun Takizawa, Hirohito Sone, Koichi Ohshima

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY   40 ( 11 )   1473 - 1483   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Myeloid sarcoma (MS) is an extramedullary tumor of immature myeloid cells. We analyzed 131 patients with MS, including: (1) de novo MS; (2) MS with concomitant acute myeloid leukemia (AML); (3) MS following myelodysplastic syndrome, myeloproliferative neoplasm, or chronic myelogenous leukemia; and (4) MS as a recurrence of AML. The most common development site was the lymph node. Testicular lesions were statistically more frequent in MS as a recurrence of AML than in other types of MS (P = 0.0183). MS tended to lack myeloid markers (myeloperoxidase was present in 63.2%, CD68 in 51.3%, CD13 in 48.7%, and CD33 in 48.7% of patients) and express T-cell markers such as CD3 (20.7%) and CD5 (34.2%). All T-cell marker-positive MS cases were negative for the alpha beta and gamma delta T-cell receptors on immunohistochemistry. Underlying myelodysplastic syndrome or myeloproliferative neoplasm was a poor prognostic factor (vs. de novo MS: P = 0.0383; vs. MS with concomitant AML: P = 0.0143). However, there was no statistical difference in prognosis between de novo MS and MS with concomitant AML (P = 0.288). There were no significant differences in prognosis between the prognoses of T-cell marker-positive and T-cell marker-negative MS cases. In addition, CXCR4 expression was a poor prognostic factor in MS (P = 0.0229). This study involves the largest MS cohort to date and expands the clinical and pathologic knowledge of the disease.

    DOI: 10.1097/PAS.0000000000000727

    Web of Science

    PubMed

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 輸血依存患者における肝臓内鉄含有量を評価するための二重エネルギーCTの重要性(Significance of dual-energy CT to evaluate liver iron content in transfusion-dependent patients)

    Kobayashi Hironori, Yoshimura Norihiko, Suwabe Tatsuya, Katagiri Takayuki, Miyakoshi Shukuko, Ushiki Takashi, Fuse Kyoko, Shibasaki Yasuhiko, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   57 ( 9 )   1524 - 1524   2016.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma Reviewed

    Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Naoya Nakamura, Koichi Ohshima, Hirohito Sone, Jun Takizawa

    CANCER SCIENCE   107 ( 6 )   853 - 861   2016.6

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Genomic alterations and protein expression levels have been established as prognostic factors for survival in patients with diffuse large B-cell lymphoma (DLBCL). In particular, double-hit DLBCL (DHL), which exhibits translocations in MYC and BCL2 and/or BCL6, is known to be associated with a poor prognosis. However, the clinical significance of gene alterations and protein expression levels for MYC, B-cell lymphoma (BCL)2, and BCL6 are unclear. In this study, we analyzed 61 adult patients diagnosed with DLBCL without DHL, who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, or similar regimens. There were no differences in the distribution of MYC expression rates among the different MYC gene statuses. In log-rank tests, MYC translocation was a prognostic factor for overall survival (OS; P = 0.011), whereas BCL2 and BCL6 translocation were not prognostic indicators (P = 0.999 and P = 0.925, respectively). Although the expression levels of MYC and BCL6 were not significantly associated with OS, the expression of BCL2 was a prognostic factor for OS (P = 0.027). Furthermore, copy number gains in the MYC, BCL2, and BCL6 genes did not affect OS. MYC translocation (hazard ratio, 4.769; range, 1.518-14.98; P = 0.007) and BCL2 protein expression (hazard ratio, 3.072; range, 1.002-9.413; P = 0.049) were independent prognostic factors for survival in multivariate analyses. In conclusion, MYC translocation and BCL2 expression may need to be investigated at the initial diagnosis to predict prognosis in patients with DLBCL.

    DOI: 10.1111/cas.12942

    Web of Science

    PubMed

    researchmap

  • Outcomes and prognostic factors of radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) for newly diagnosed, localized extranodal NK/T-cell lymphoma, nasal type (ENKL): a cooperative study in Japan. Reviewed

    Yamaguchi Motoko, Suzuki Ritsuro, Oguchi Masahiko, Asano Naoko, Amaki Jun, Maeda Takeshi, Kubota Nobuko, Kobayashi Yukio, Ueda Kyoko, Miyazaki Kana, Tomita Naoto, Sekiguchi Nodoka, Takizawa Jun, Saito Bungo, Murayama Tohru, Ando Toshihiko, Wada Hideho, Hyo Rie, Hasegawa Masatoshi, Katayama Naoyuki

    JOURNAL OF CLINICAL ONCOLOGY   34 ( 15 )   2016.5

  • Clinical Significance of MYC, BCL2 and BCL6 Rearrangement and Protein Expression in GCB and Non-GCB Type Diffuse Large B-Cell Lymphoma Invited Reviewed

    Kawamoto Keisuke, Takizawa Jun, Miyoshi Hiroaki, Yoshida Noriaki, Shibasaki Yasuhiko, Masuko Masayoshi, Sone Hirohito, Nakamura Naoya, Ohshima Koichi

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma Reviewed

    T. Aoki, K. Shimada, R. Suzuki, K. Izutsu, A. Tomita, Y. Maeda, J. Takizawa, K. Mitani, T. Igarashi, K. Sakai, K. Miyazaki, K. Mihara, K. Ohmachi, N. Nakamura, H. Takasaki, H. Kiyoi, S. Nakamura, T. Kinoshita, M. Ogura

    BLOOD CANCER JOURNAL   5   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    DOI: 10.1038/bcj.2015.101

    Web of Science

    PubMed

    researchmap

  • Fatal tracheal aspergillosis during rituximab combined chemotherapy for diffuse large B-cell lymphoma that developed after lung transplantation Reviewed

    K. Kawamoto, Y. Shibasaki, S. Sato, H. Nemoto, J. Takizawa, M. Narita, M. Tsuchida, H. Sone, M. Masuko

    TRANSPLANT INFECTIOUS DISEASE   17 ( 6 )   872 - 875   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Invasive tracheal aspergillosis (ITA) is an infection that is unique to patients who have undergone lung transplantation (LT). Although the activity of this disease often appears on imaging, we encountered a case of ITA that became exacerbated, despite few computed tomography (CT) findings, during rituximab combined chemotherapy for diffuse large B-cell lymphoma. ITA developed during immunosuppressive therapy after LT. Because CT findings may show false-negative results, bronchoscopy is recommended for such cases.

    DOI: 10.1111/tid.12458

    Web of Science

    PubMed

    researchmap

  • レシピエントに対する移植前評価としてのHCT-CI/年齢スコアの臨床的意義(The clinical relevance of HCT-CI/age score as pre-transplant assessment for recipients)

    Katagiri Takayuki, Shibasaki Yasuhiko, Suwabe Tatsuya, Miyakoshi Shukuko, Fuse Kyoko, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   56 ( 9 )   1665 - 1665   2015.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • HSCT後のγ/δT細胞低値およびTreg細胞高値はいずれも再発の独立リスク因子である(Both low γ/δ T cells and high Treg cells after HSCT is an independent risk factor for relapse)

    Shibasaki Yasuhiko, Miyakoshi Syukuko, Suwabe Tatsuya, Katagiri Takayuki, Fuse Kyoko, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Furukawa Tatsuo, Masuko Masayoshi

    臨床血液   56 ( 9 )   1666 - 1666   2015.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Possible Involvement of Lung Cells Harboring an Abnormal Karyotype in the Pathogenesis of Pulmonary Alveolar Proteinosis Associated with Myelodysplastic Syndrome.

    Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, Takizawa J, Sone H, Tazawa R, Saijo Y, Ishii H, Nakata K

    Ann Am Thorac Soc   12 ( 8 )   1251 - 1253   2015.8

  • The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients. Reviewed International journal

    Shibasaki Y, Seki Y, Tanaka T, Miyakoshi S, Fuse K, Kozakai T, Kobayashi H, Ushiki T, Abe T, Yano T, Moriyama M, Kuroha T, Isahai N, Takizawa J, Narita M, Koyama S, Furukawa T, Sone H, Masuko M

    Leukemia research   39 ( 6 )   667 - 671   2015.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We focused on the level of reduction of Wilms' tumor gene 1 (WT1) mRNA in bone marrow as minimal residual disease during chemotherapies in adult acute myeloid leukemia (AML) patients. Forty-eight patients were enrolled in this study. Log levels of reduction of WT1 mRNA transcript after induction therapy compared with those at diagnosis were associated with disease-free survival (DFS) (P=0.0066) and overall survival (OS) (P=0.0074) in patients who achieved complete remission. Also log levels of reduction of WT1 mRNA transcript after final consolidation therapy compared with those at diagnosis were associated with DFS (P=0.015) and OS (P=0.012). By multivariate analysis, log levels of reduction of WT1 mRNA transcript after induction therapy and after final consolidation therapy compared with those at diagnosis were extracted as risk factors for outcome. Our results suggest that early and deep reduction of tumor burden may be important for the outcome of AML patients. In addition, it may be useful for the decision to proceed with allogeneic SCT as post-remission therapy.

    DOI: 10.1016/j.leukres.2015.03.021

    PubMed

    researchmap

  • 鼠径部皮下腫瘤から診断されたびまん性大細胞型B細胞リンパ腫の1例

    吉長 由季菜, 藤川 大基, 株本 武範, 伊藤 雅章, 片桐 隆幸, 瀧澤 淳

    日本皮膚科学会雑誌   125 ( 4 )   947 - 947   2015.4

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    researchmap

  • Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia. Reviewed

    Fuse K, Matsuyama Y, Moriyama M, Miyakoshi S, Shibasaki Y, Takizawa J, Furukawa T, Fuse I, Matsumura H, Uchida S, Takahashi Y, Kamimura K, Abe H, Suda T, Aoyagi Y, Sone H, Masuko M

    Internal medicine (Tokyo, Japan)   54 ( 6 )   657 - 661   2015

  • Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan Reviewed

    Tomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, Chiaki Nakaseko, Hiroshi Arima, Kazuyuki Shimada, Akihiro Tomita, Makoto Sasaki, Jun Takizawa, Kinuko Mitani, Tadahiko Igarashi, Yoshinobu Maeda, Noriko Fukuhara, Fumihiro Ishida, Nozomi Niitsu, Ken Ohmachi, Hirotaka Takasaki, Naoya Nakamura, Tomohiro Kinoshita, Shigeo Nakamura, Michinori Ogura

    HAEMATOLOGICA   99 ( 12 )   1817 - 1825   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:FERRATA STORTI FOUNDATION  

    The prognosis of patients with primary mediastinal large B-cell lymphoma has improved over recent years. However, the optimal treatment strategy including the role of radiotherapy remains unknown. We retrospectively analyzed the clinical outcomes of 345 patients with newly diagnosed primary mediastinal large B-cell lymphoma in Japan. With a median follow up of 48 months, the overall survival at four years for patients treated with R-CHOP (n=187), CHOP (n=44), DA-EPOCH-R (n=9), 2nd- or 3rd-generation regimens, and chemotherapy followed by autologous stem cell transplantation were 90%, 67%, 100%, 91% and 92%, respectively. Focusing on patients treated with R-CHOP, a higher International Prognostic Index score and the presence of pleural or pericardial effusion were identified as adverse prognostic factors for overall survival in patients treated with R-CHOP without consolidative radiotherapy (IPI: hazard ratio 4.23, 95% confidence interval 1.48-12.13, P=0.007; effusion: hazard ratio 4.93, 95% confidence interval 1.37-17.69, P=0.015). Combined with the International Prognostic Index score and the presence of pleural or pericardial effusion for the stratification of patients treated with R-CHOP without radiotherapy, patients with lower International Prognostic Index score and the absence of effusion comprised approximately one-half of these patients and could be identified as curable patients (95% overall survival at 4 years). The DA-EPOCH-R regimen might overcome the effect of these adverse prognostic factors. Our simple indicators of International Prognostic Index score and the presence of pleural or pericardial effusion could stratify patients with primary mediastinal large B-cell lymphoma and help guide selection of treatment.

    DOI: 10.3324/haematol.2014.111203

    Web of Science

    PubMed

    researchmap

  • Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy Reviewed

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual-Energy CT Reviewed

    Hironori Kobayashi, Norihiko Yoshimura, Takashi Ushiki, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Activation of the Leukemia Plasmacytoid Dendritic Cell Line PMDC05 by Toho-1, a Novel IDO Inhibitor Reviewed

    Akie Yamahira, Miwako Narita, Minami Iwabuchi, Takayoshi Uchiyama, Shunpei Iwaya, Rie Ohiwa, Yoshinori Nishizawa, Takafumi Suzuki, Yusaku Yokoyama, Shigeo Hashimoto, Jun Takizawa, Hirohito Sone, Masuhiro Takahashi

    ANTICANCER RESEARCH   34 ( 8 )   4021 - 4028   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:INT INST ANTICANCER RESEARCH  

    Background/Aim: Indoleamine-2,3-dioxygenase (IDO) is a rate-limiting enzyme for tryptophan metabolism and plays an immunosuppressive role. Antigen-presenting cells, when activated, increase the expression of IDO, which results in the suppression of subsequent immune reaction. A novel IDO inhibitor, Toho-1, was explored for its applicability to immunotherapy. Materials and Methods: We investigated the effects of Toho-1 on antigen presentation and antigen-specific cytotoxic T-lymphocyte-inducing ability of leukemia plasmacytoid dendritic cell line PMDC05, which was established in our laboratory. Results: While antigen presentation-associated molecules in PMDC05 cells were increased by stimulation with lipopolysaccharide and interferon-gamma, IDO mRNA and protein expression were also enhanced. Such treatment of PMDC05 cells in combination with Toho-1 enhanced the antigen-presenting and CTL-inducing ability of PMDC05 cells. Conclusion: These findings suggest the ability of Toho-1 to potentiate antigen-presenting cells and its applicability in immunotherapy of cancer.

    Web of Science

    PubMed

    researchmap

  • Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways Reviewed

    Harumi Kato, Kennosuke Karube, Kazuhito Yamamoto, Jun Takizawa, Shinobu Tsuzuki, Yasushi Yatabe, Teru Kanda, Miyuki Katayama, Yukiyasu Ozawa, Kenji Ishitsuka, Masataka Okamoto, Tomohiro Kinoshita, Koichi Ohshima, Shigeo Nakamura, Yasuo Morishima, Masao Seto

    CANCER SCIENCE   105 ( 5 )   537 - 544   2014.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly (EBV[+]DLBCL-E) is classified as a subtype of DLBCL. Until now, its molecular pathogenesis has remained unknown. To identify pathways characteristic of EBV(+)DLBCL-E, gene expression profiling of five EBV(+)DLBCL-E and seven EBV-negative DLBCL (EBV[-]DLBCL) cases was undertaken using human oligonucleotide microarray analysis. Gene set enrichment analysis and gene ontology analysis showed that gene sets of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and nuclear factor kappa B (NF-B) pathways were enriched in EBV(+)DLBCL-E cases. To confirm the results of the expression profiles, in vitro analysis was performed. Expression profiling analysis showed that high activation of the JAK-STAT and NF-B pathways was induced by EBV infection into DLBCL cell lines. Activation of the NF-B pathway was confirmed in EBV-infected cell lines using an electrophoretic mobility shift assay. Western blot analysis revealed an increased protein expression level of phosphorylated signal transducer and activator of transcription 3 (STAT3) in an EBV-infected cell line. Protein expression of phosphorylated STAT3 was frequently observed in lymphoma cells of EBV(+)DLBCL-E clinical samples using immunohistochemistry (EBV[+]DLBCL-E: 80.0% [n=20/25] versus EBV[-]DLBCL: 38.9% [n=14/36]; P=0.001). The results of the present study suggest that activation of the JAK-STAT and NF-B pathways was characteristic of EBV(+)DLBCL-E, which may reflect the nature of EBV-positive tumor cells. Targeting these pathways as therapies might improve clinical outcomes of EBV(+)DLBCL-E.

    DOI: 10.1111/cas.12389

    Web of Science

    researchmap

  • Early Diagnosis of Hepatic Intravascular Lymphoma: A Case Report and Literature Review Reviewed

    Hiroyuki Abe, Kenya Kamimura, Maiko Mamizu, Yasuhiko Shibazaki, Takanobu Ishiguro, Shin-ichi Katada, Yu-ki Nishiyama, Yoshifumi Takahashi, Yu-ya Hatano, Ken-ichi Mizuno, Yukari Watanabe, Aiko Nagashima, Jun Takizawa, Manabu Takeuchi, Hirokazu Kawai, Minoru Nomoto, Hirohito Sone, Masatoyo Nishizawa, Yutaka Aoyagi

    INTERNAL MEDICINE   53 ( 6 )   587 - 593   2014

     More details

    Language:English   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Hepatic intravascular large B-cell lymphoma (IVL) is a rare disease entity that involves invasion into various organs. Due to the aggressive behavior and poor prognosis of the disease and the difficulty in making an early diagnosis, some cases are diagnosed at autopsy. Early suspicion and the use of imaging studies and liver biopsies are key for diagnosing IVL; however, no reports have described the results of imaging studies due to the limited number of cases. We herein report the results of imaging studies of hepatic IVL, including the findings PET-CT, dynamic-CT, EOB-MRI and CEUS. These results may help physicians to make an early diagnosis and improve the prognosis.

    DOI: 10.2169/internalmedicine.53.1812

    Web of Science

    PubMed

    researchmap

  • Manifestations of Fulminant CD8 T-cell Post-transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Tomoyuki Tanaka, Jun Takizawa, Shukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, Koichi Ohshima, Ken Toba, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    INTERNAL MEDICINE   53 ( 18 )   2115 - 2119   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a 22-year-old woman with severe aplastic anemia who underwent allogeneic hematopoietic stem cell transplantation (HSCT). After HSCT, the Epstein-Barr virus (EBV)-DNA load in the peripheral blood gradually increased, and the patient presented with a fever and lymphadenopathy on day 56 post-HSCT. Although we administered rituximab, her clinical condition worsened. After rituximab treatment, CD8 T-cells emerged and became dominant in the peripheral blood, some of which were positive on an EBV-specific tetramer analysis. However, an open biopsy of the lymphadenopathy lesions revealed the CD8 T-cells to be infected with EBV, exhibiting proliferation with oligoclonality. The patient ultimately died of multiple organ failure on day 99 post-HSCT.

    DOI: 10.2169/internalmedicine.53.2384

    Web of Science

    PubMed

    researchmap

  • Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine. Reviewed

    Okazuka K, Masuko M, Matsuo Y, Miyakoshi S, Tanaka T, Kozakai T, Kobayashi H, Fuse K, Shibasaki Y, Moriyama M, Takizawa J, Fuse I, Toba K, Furukawa T

    Intern Med   52 ( 11 )   1239 - 1242   2013.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Internal Medicine  

    A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP.<br>

    DOI: 10.2169/internalmedicine.52.0080

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014315593

  • MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: Multicenter analysis of Japanese patients with diffuse large B-cell lymphoma Reviewed

    Minoru Kojima, Hidekazu Nishikii, Jun Takizawa, Sadao Aoki, Masayuki Noguchi, Shigeru Chiba, Kiyoshi Ando, Naoya Nakamura

    Leukemia and Lymphoma   54 ( 10 )   2149 - 2154   2013.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and it has several morphologic and clinicopathologic variants. The prognosis of DLBCL can vary according to specific genetic and immunophenotypic abnormalities. The aim of this study was to investigate the prognostic impact of previously identified prognostic factors, such as activated B cell-like immunophenotype, CD5, BCL2 and MYC rearrangement (MYC-R), in patients treated with rituximab. We retrospectively analyzed the prognosis of 100 patients with DLBCL (median age, 66.5 years) treated with rituximab-containing chemotherapy. The 3-year overall survival (OS) and progression-free survival (PFS) were 66% and 62%. Outcomes were significantly worse in patients with MYC-R in 3-year OS (50% vs. 67.8%, p = 0.043) and PFS (30% vs. 57.8%, p = 0.003), and multivariate analysis showed that this finding was independent of the International Prognostic Index (IPI). Immunostaining by Muris algorithm had the highest predictive power among the three algorithms. However, other previously reported prognostic factors, such as BCL2 and CD5, were not good predictors of outcomes in these patients. In conclusion, our data suggest that fluorescence in situ hybridization (FISH) analysis for MYC-R can predict outcomes in response to rituximab-containing chemotherapy in Japanese patients with DLBCL. © 2013 Informa UK, Ltd.

    DOI: 10.3109/10428194.2013.771398

    Scopus

    PubMed

    researchmap

  • Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma. Reviewed International journal

    Ogura R, Aoki H, Natsumeda M, Shimizu H, Kobayashi T, Saito T, Takizawa J, Okamoto K, Hasegawa G, Umezu H, Ohshima K, Takahashi H, Fujii Y, Kakita A

    Neuropathology : official journal of the Japanese Society of Neuropathology   33 ( 4 )   436 - 441   2013.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Primary central nervous system lymphoma (PCNSL) expressing T-cell markers is rare, among which nasal-type extranodal NK/T-cell lymphoma is an extremely rare subtype associated with Epstein-Barr virus (EBV) infection. Here we report the clinicopathologic features of a case of EBV-associated PCNSL showing a cytotoxic T-cell phenotype. The patient, a 73-year-old woman, presented with rapidly progressive mental deterioration. Brain MRI revealed multiple lesions with swelling in the bilateral cerebral hemispheres, which were hypointense on T1-weighted images, hyperintense on T2-weighted and fluid-attenuated inversion recovery images, and slightly hyperintense on diffusion-weighted images. Biopsy specimens from the temporal region showed many medium-sized anaplastic lymphocytic cells with perivascular and angio-invasive patterns in the cortex. Immunohistochemically, the cells were positive for CD3, CD8, T-cell-restricted intracellular antigen-1 (TIA-1), granzyme B and perforin, but negative for CD56 and CD20. In situ hybridization revealed EBV-encoded RNAs in the tumor cell nuclei. A rearrangement study showed T-cell receptor γ-chain gene rearrangement with a clonal appearance. The patient died 6 months after surgery, and a general autopsy revealed no lymphoma cells outside the brain. These cellular profiles are inconsistent with those of extranodal NK/T-cell lymphoma, and have not been previously described. This case appears to represent an unusual CNS manifestation of EBV-associated T-cell lymphoma.

    DOI: 10.1111/neup.12005

    PubMed

    researchmap

  • 血液悪性腫瘍患者における真菌感染症に対するvoriconazoleの有効性と安全性(Efficacy and safety of Voriconazole on fungal infections in patients with hematological malignancies)

    Miyakoshi Shukuko, Takizawa Jun, Seki Yoshinobu, Maruyama Souichi, Karimata Kaori, Kobayashi Hironori, Ida Tori, Momoi Akihito, Yano Toshio, Kuroha Takashi, Ushiki Takashi, Nikkuni Koji, Nomoto Nobuhiko, Nagai Koichi, Aoki Sadao

    臨床血液   53 ( 9 )   1092 - 1092   2012.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type Reviewed

    Yoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda, Chizuko Hashimoto, Fumihiro Ishida, Koji Izutsu, Noriyasu Fukushima, Yasushi Isobe, Jun Takizawa, Yuichi Hasegawa, Hajime Kobayashi, Seiichi Okamura, Hikaru Kobayashi, Motoko Yamaguchi, Junji Suzumiya, Rie Hyo, Shigeo Nakamura, Keisei Kawa, Kazuo Oshimi, Ritsuro Suzuki

    CLINICAL CANCER RESEARCH   18 ( 15 )   4183 - 4190   2012.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC CANCER RESEARCH  

    Purpose: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein-Barr virus (EBV)-associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) recently showed promising results.
    Experimental Design: The amount of EBV-DNA was prospectively measured in whole-blood and plasma samples by real-time quantitative PCR from 26 patients registered in the SMILE phase II study.
    Results: Before treatment, the EBV-DNA was detected in 22 samples of whole blood with a median number of 3,691 copies/mL (range: 0-1.14 x 10(7)), but 15 samples of plasma with a median of 867 copies/mL (range: 0-1.27 x 10(7)). Results of these 2 measurements of EBV-DNA well correlated (R-2 = 0.994, P &lt; 0.001). The overall response rate to SMILE was significantly higher in patients with less than 10(5) copies/mL of EBV-DNA in whole blood at enrollment (90% vs. 20%, P = 0.007) and in patients with less than 10(4) copies/mL of EBV-DNA in plasma (95% vs. 29%, P = 0.002). The incidence of grade 4 toxicity of SMILE other than leukopenia/neutropenia was significantly higher in patients with 10(5) copies/mL of EBV-DNA or more in whole blood (100% vs. 29%, P = 0.007) than that of others and in patients with 10(4) copies/mL or more in plasma (86% vs. 26%, P = 0.002).
    Conclusions: These findings suggest that whole blood is more sensitive for clinical use than plasma. The EBV-DNA amount in whole blood was useful for predicting tumor response, toxicity, and prognosis after SMILE chemotherapy for ENKL. Clin Cancer Res; 18(15); 4183-90. (C)2012 AACR.

    DOI: 10.1158/1078-0432.CCR-12-1064

    Web of Science

    researchmap

  • IgM-type GM-CSF autoantibody is etiologically a bystander but associated with IgG-type autoantibody production in autoimmune pulmonary alveolar proteinosis Reviewed

    Takahito Nei, Shinya Urano, Natsuki Motoi, Jun Takizawa, Chinatsu Kaneko, Hiroko Kanazawa, Ryushi Tazawa, Kazuhide Nakagaki, Kiyoko S. Akagawa, Keiichi Akasaka, Toshio Ichiwata, Arata Azuma, Koh Nakata

    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY   302 ( 9 )   L959 - L964   2012.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER PHYSIOLOGICAL SOC  

    Nei T, Urano S, Motoi N, Takizawa J, Kaneko C, Kanazawa H, Tazawa R, Nakagaki K, Akagawa KS, Akasaka K, Ichiwata T, Azuma A, Nakata K. IgM-type GM-CSF autoantibody is etiologically a bystander but associated with IgG-type autoantibody production in autoimmune pulmonary alveolar proteinosis. Am J Physiol Lung Cell Mol Physiol 302: L959-L964, 2012. First published February 24, 2012; doi: 10.1152/ajplung.00378.2011.-The granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody (GMAb) is the causative agent underlying autoimmune pulmonary alveolar proteinosis (aPAP). It consists primarily of the IgG isotype. At present, information on other isotypes of the autoantibody is limited. We detected serum the IgM isotype of GMAb (IgM-GMAb) in more than 80% of patients with aPAP and 22% of healthy subjects, suggesting that a continuous antigen pressure may be present in most patients. Levels of the IgM isotype were weakly correlated with IgG-GMAb levels but not IgA-GMAb, suggesting that its production may be associated with that of IgG-GMAb. The mean binding avidity to GM-CSF of the IgM isotype was 100-fold lower than the IgG-GMAb isotype, whereas the IC50 value for neutralizing capacity was 20,000-fold higher than that of IgG-GMAb, indicating that IgM-GMAb is only a very weak neutralizer of GM-CSF. In bronchoalveolar lavage fluid from nine patients, IgG-GMAb was consistently detected, but IgM-GMAb was under the detection limit in most patients, confirming that IgM-GMAb is functionally a bystander in the pathogenesis of aPAP. It rather may be involved in the mechanism for development of IgG-GMAb in vivo.

    DOI: 10.1152/ajplung.00378.2011

    Web of Science

    researchmap

  • Idiopathic Macrocytosis in Smokers

    Takahashi Masuhiro, Yamahira Akie, Uchiyama Takayoshi, Iwabuchi Minami, Sato Naoya, Takizawa Jun, Sone Hirohito, Narita Miwako

    Official Journal of the Japanese Society of Human Dry Dock   27 ( 4 )   689 - 696   2012

     More details

    Language:Japanese   Publisher:Japan Society of Ningen Dock  

    <b>Objective:</b> Smoking has been reported to be one of the risk factors of myelodysplastic syndrome (MDS). In order to clarify the process of progression to MDS in a certain group of smokers, it is important to identify the initial hematological abnormalities associated with the early stage of MDS in smokers. <br><b>Methods:</b> Relationships of hematological parameters such as WBC count, RBC count, Hb, Ht, MCH and MCV with level of smoking were investigated by univariate and multivariate analyses in 234 male workers at a single workplace after obtaining informed consent.<br><b>Results:</b> Univariate analysis demonstrated that correlations of smoking-related factors (number of cigarettes per day, duration of smoking [years] and smoking index [defined as number of cigarettes per day x duration of smoking]) with WBC count, Ht, MCH and MCV were significantly positive. Multivariate analysis using age, smoking-related factors, alcohol intake and BMI as explanatory valuables showed that age, alcohol intake and BMI were not confounding variables for smoking-related factors and revealed a remarkable significant positive correlation between each smoking-related factor and MCV.<br><b>Conclusion:</b> Smoking-associated macrocytosis, which was demonstrated in the present study, was not due to deficiency of vitamin B<sub>12</sub> or folic acid because of no pancytopenia observed but was considered to be a qualitative abnormality of erythrocytes. Taken together with the findings of previous studies concerning smoking-associated functional abnormalities of erythrocytes and leukocytes and the high incidence of MDS in smokers, our results indicate that idiopathic macrocytosis in smokers could be an initial sign of progression to MDS, in which macrocytosis and multi-lineage abnormalities are characteristic findings.

    DOI: 10.11320/ningendock.27.689

    CiNii Article

    CiNii Books

    researchmap

    Other Link: https://jlc.jst.go.jp/DN/JALC/10013821561?from=CiNii

  • 4. MALTリンパ腫による転移性気管腫瘍の1例(第54回 日本呼吸器内視鏡学会北陸支部会)

    三浦 理, 森山 寛史, 星野 芳史, 小屋 俊之, 中山 秀章, 各務 博, 高田 俊範, 成田 一衛, 吉永 清宏, 小堺 貴司, 瀧澤 淳, 鈴木 栄一, 味岡 洋一

    気管支学   34 ( 4 )   407 - 407   2012

     More details

    Language:Japanese   Publisher:特定非営利活動法人 日本呼吸器内視鏡学会  

    DOI: 10.18907/jjsre.34.4_407_4

    CiNii Article

    researchmap

  • Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan Reviewed

    Katsuhiro Miura, Hirotaka Takasaki, Hideki Tsujimura, Masatoshi Kanno, Yoshinobu Maeda, Naoto Tomita, Kazue Takai, Yasufumi Masaki, Jun Takizawa, Hiraku Mori, Yasushi Terasaki, Takashi Yoshida, Jin Takeuchi, Shigeki Motomura

    INTERNATIONAL JOURNAL OF HEMATOLOGY   93 ( 5 )   684 - 686   2011.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    DOI: 10.1007/s12185-011-0845-4

    Web of Science

    researchmap

  • Multifocal mucosa-associated lymphoid tissue lymphoma associated with IgG4-related disease: a case report Reviewed

    Tokuhide Oyama, Jun Takizawa, Naoya Nakamura, Sadao Aoki, Yoshifusa Aizawa, Haruki Abe

    JAPANESE JOURNAL OF OPHTHALMOLOGY   55 ( 3 )   304 - 306   2011.5

     More details

    Language:English   Publisher:SPRINGER TOKYO  

    DOI: 10.1007/s10384-011-0003-9

    Web of Science

    PubMed

    researchmap

  • Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis Reviewed

    Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, Shigeru Kusumoto, Masataka Okamoto, Masahiro Yokoyama, Yasushi Takamatsu, Kazutaka Sunami, Akira Miyata, Kayoko Murayama, Akira Sakai, Morio Matsumoto, Katsuji Shinagawa, Akinobu Takaki, Keitaro Matsuo, Tomohiro Kinoshita, Mitsune Tanimoto

    BLOOD   116 ( 24 )   5119 - 5125   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEMATOLOGY  

    The influence of hepatitis C virus (HCV) infection on prognosis and hepatic toxicity in patients with diffuse large B-cell lymphoma in the rituximab era is unclear. Thus, we analyzed 553 patients, 131 of whom were HCV-positive and 422 of whom were HCV-negative, with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)-like chemotherapy. Survival outcomes and hepatic toxicity were compared according to HCV infection. The median follow-up was 31 and 32 months for patients who were HCV-positive and HCV-negative, respectively. HCV infection was not a significant risk factor for prognosis (3-year progression-free survival, 69% vs 77%, P = .22; overall survival, 75% vs 84%, P = .07). Of 131 patients who were HCV-positive, 36 (27%) had severe hepatic toxicity (grade 3-4), compared with 13 of 422 (3%) patients who were HCV-negative. Multivariate analysis revealed that HCV infection was a significant risk factor for severe hepatic toxicity (hazard ratio: 14.72; 95% confidence interval, 6.37-34.03; P &lt; .001). An exploratory analysis revealed that pretreatment transaminase was predictive of severe hepatic toxicity. HCV-RNA levels significantly increased during immunochemotherapy (P = .006). These results suggest that careful monitoring of hepatic function and viral load is indicated during immunochemotherapy for HCV-positive patients. (Blood. 2010;116(24):5119-5125)

    DOI: 10.1182/blood-2010-06-289231

    Web of Science

    researchmap

  • Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single timepoint for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation. Reviewed

    Furukawa T, Kurasaki-Ida T, Masuko M, Tsukada N, Okazuka K, Sato N, Yano T, Abe T, Momoi A, Shibasaki Y, Higashimura M, Karimata K, Moriyama M, Kuroha T, Takizawa J, Toba K, Narita M, Fuse I, Takahashi M, Aizawa Y

    Int J Hematol.   92 ( 1 )   144 - 151   2010.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-010-0610-0

    CiNii Article

    CiNii Books

    researchmap

  • 咽頭・気管に再発した肺MALTリンパ腫の1例 Reviewed

    田中 淳一, 田島 俊児, 梶原 大季, 茂呂 寛, 成田 淳一, 田邊 嘉也, 各務 博, 中山 秀章, 寺田 正樹, 高田 俊範, 成田 一衛, 瀧澤 淳, 長谷川 隆志, 鈴木 栄一, 中村 直哉, 手塚 貴文, 今井 洋介

    気管支学   32 ( 1 )   84 - 84   2010.1

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器内視鏡学会  

    researchmap

  • Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system - Laboratory investigation Reviewed

    Jie Li, Hiroaki Okamoto, Chunyue Yin, Jay Jagannathan, Jun Takizawa, Sadao Aoki, Sven Glaesker, Elisabeth J. Rushing, Alexander O. Vortmeyer, Edward H. Oldfield, Ryuya Yamanaka, Zhengping Zhuang

    JOURNAL OF NEUROSURGERY   109 ( 3 )   536 - 546   2008.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC NEUROLOGICAL SURGEONS  

    Object. The lack of primary lymphoid tissue within the central nervous system (CNS) confounds our understanding of the pathogenesis of primary CNS lymphomas (PCNSLs). Comparing the protein expression of PCNSLs and sporadic systemic lymphomas (SSLs) provides a useful strategy for identifying a molecular signature that characterizes disease-associated features and provides information regarding tumor initiation and progression.
    Methods. Seven diffuse large B-cell PCNSLs were selected to undergo 2D gel electrophoresis, and profiled proteomes from these PCNSLs were compared with those from 7 diffuse large B-cell SSLs. Distinguishing proteins were sequenced using mass spectrometry.
    Results. Two-dimensional get electrophoresis identified an average of 706 proteins from each specimen. Computerized gel analysis and manual reconfirmation revealed a 96% similarity in the proteomes of PCNSLs and SSLs. Comparative analysis identified 9 proteins significantly overexpressed (p &lt; 0.05) and 16 proteins downregulated in PCNSLs. The proteomic findings were further validated using Western blot and immunohistochemical staining.
    Conclusions. The similarities in proteomic patterns between PCNSLs and SSLs suggest that these tumor types share structural similarities, acquired during differentiation. The ultimate fate of lymphomatous cells (CNS vs systemic) may be related to differentially expressed proteins, which function in homing and host processing. Elucidating the roles of these differentially expressed proteins will prove valuable in understanding the pathogenesis of PCNSL.

    DOI: 10.3171/JNS/2008/109/9/0536

    Web of Science

    researchmap

  • Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma Reviewed

    Anri Saitoh, Miwako Narita, Norihiro Watanabe, Nozomi Tochiki, Noriyuki Satoh, Jun Takizawa, Tatsuo Furukawa, Ken Toba, Yoshifusa Aizawa, Shohji Shinada, Masuhiro Takahashi

    MEDICAL ONCOLOGY   25 ( 2 )   137 - 147   2008.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:HUMANA PRESS INC  

    In order to establish an efficient gamma delta T cell-mediated immunotherapy for hematological malignancies, we attempted to evaluate cytotoxicity against tumor cells by gamma delta T cells, which were generated from blood cells of patients with myeloma and lymphoma by culturing with zoledronate and a low dose of IL-2. Although gamma delta T cells were expanded in patients with myeloma and lymphoma as well as normal persons, the amplification rates of gamma delta T cells before and after culturing varied from patient to patient in myeloma and lymphoma. gamma delta T cells generated in patients with myeloma and lymphoma showed a potent cytotoxic ability against myeloma/lymphoma cell lines as shown in gamma delta T cells generated in normal subjects. In addition, gamma delta T cells generated in a patient with myeloma showed a cytotoxic ability against self myeloma cells freshly prepared from bone marrow. However, the same gamma delta T cells were demonstrated to be non-cytotoxic to normal cells of the patient. These data demonstrated that gamma delta T cells, which could be expanded in vitro from blood cells of patients with myeloma and lymphoma by culturing with zoledronate and IL-2, possess a sufficient cytotoxic ability against tumor cells. These findings suggested that in vitro generated patients&apos; gamma delta T cells could be applied to gamma delta T cell-mediated immunotherapy for hematological malignancies.

    DOI: 10.1007/s12032-007-9004-4

    Web of Science

    researchmap

  • 長期間左内頸CVカテーテル留置により発生し、右心房直上まで及んだ巨大血栓に対して大静脈フィルターを用い、救命し得た1例

    岡本 竹司, 榛澤 和彦, 佐藤 浩一, 林 純一, 瀧澤 淳, 桃井 明仁, 下田 傑, 布施 一郎

    新潟医学会雑誌   122 ( 5 )   288 - 288   2008.5

  • Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation Reviewed

    Jun Takizawa, Sadao Aoki, Tori Kurasaki, Masutaka Higashimura, Keiichiro Honma, Toshiki Kitajima, Akihito Momoi, Hidenobu Takahashi, Naoya Nakamura, Tatsuo Furukawa, Yoshifusa Aizawal

    AMERICAN JOURNAL OF HEMATOLOGY   82 ( 12 )   1113 - 1115   2007.12

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-LISS  

    This study reports the first well-documented case of adult T-cell leukemia (ATL) successfully treated with unrelated cord blood transplantation (UCBT). A 49-year-old woman was diagnosed with acute-type of ATL. Chemotherapy induced complete remission, but the human T-cell leukemia virus type 1 (HTLV-1) proviral load was detected in mononuclear cells of her peripheral blood. The patient received UCBT with a conditioning regimen consisting of total body irradiation, cytarabine, and cyclophosphamide. She remains in remission 30 months after UCBT and the HTLV-1 proviral load has fallen to undetectable levels. This result suggests that UCBT should be a therapeutic option for ATL patients who do not have suitable donors and those who urgently require treatment. Am. J. Hematol. 82:1113-1115, 2007. (c) 2007 Wiley-Liss, Inc.

    DOI: 10.1002/ajh.21042

    Web of Science

    PubMed

    researchmap

  • Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. Reviewed

    Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Fuse I, Aizawa Y, Shinada S, Takahashi M

    J Clin Exp Hematop.   47 ( 2 )   61 - 72   2007.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society for Lymphoreticular Tissue Research  

    In order to establish the method of generating powerful γδ T cells for anti-tumor immunotherapy, we investigated the effects of monocyte-derived dendritic cells (mo-DCs) on anti-tumor cytotoxicity of expanded γδ T cells. Activation of γδ T cells co-cultured for 2-3 days with immature or mature mo-DCs was evaluated by CD69 expression and anti-tumor cytotoxicity using two assays : the 5- (and 6-) carboxyfluorescein diacetate, succinimidyl ester-based cytotoxicity assay and the calcein-AM-based Terascan assay. γδ T cells were used as effector cells and myeloma cell line (RPMI8226) or chronic myelogenous leukemia blastic crisis cell line (C2F8) were used as target cells. CD69 expression on γδ T cells was enhanced by co-culture with both immature and mature mo-DCs in a cell-number-dependent fashion. CD69 expression was enhanced after addition of mo-DCs of either autologous or allogeneic origin. Activation of γδ T cells with mo-DCs enhanced anti-tumor cytotoxicity of γδ T cells against RPMI8226 and C2F8 in an effector-to-target ratio-dependent manner. Activation of γδ T cells by mo-DCs was associated with the enhancement of anti-tumor cytotoxicity of γδ T cells. Potent γδ T cells activated by mo-DCs were considered to be applicable to an efficient γδ T cell-mediated immunotherapy for tumors. [<I>J Clin Exp Hematopathol 47(2) </I><I>: 61</I>-<I>72, 2007</I>]

    DOI: 10.3960/jslrt.47.61

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2008186007

  • Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients Reviewed

    Hidenobu Takahashi, Tatsuo Furukawa, Toshio Yano, Naoko Sato, Jun Takizawa, Tori Kurasaki, Takashi Abe, Miwako Narita, Masayoshi Masuko, Satoru Koyama, Ken Toba, Masuhiro Takahashi, Yoshifusa Aizawa

    EXPERIMENTAL HEMATOLOGY   35 ( 7 )   1091 - 1099   2007.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Objective. To identify leukemia-associated antigens, we applied the serological identification of antigens by the recombinant expression cloning (SEREX) method to a chronic myelogenous leukemia (CML) patient who achieved a cytogenetic response to interferon-alpha.
    Materials and Methods. Immunoscreening of the cDNA library was performed with sera from a CML patient. Two isolated antigens were used to evaluate the expression pattern using Northern blot analysis and quantitative reverse transcriptase polymerase chain reaction. Western blotting and enzyme-linked immunosorbent assay were also performed for serological analysis.
    Results. We identified 14 positive clones, representing five different antigens. Of these, two genes were further validated. One (clone 70) was the human polyribonucleotide nucleotidyltransferase 1 (PNPT1), which is the type I interferon (alpha/beta-responsive gene). The mRNA of clone 70 was ubiquitously expressed in normal human tissues. The other gene (clone 57) was the heat shock 70-kDa protein 4-like (HSPA4L), which is a member of the heat shock protein 110 family, whose mRNA is strongly expressed in normal human testis and overexpressed in leukemia cells. Seroactivity against HSPA4L was detected in 6 of 9 acute myeloid leukemia patients, 4 of 10 acute lymphoblastic leukemia patients, 9 of 11 CML patients, and none of 10 healthy volunteers. Leukemia patients had higher titer of the antibodies against the protein than healthy volunteers.
    Conclusions. These results suggest that HSPA4L, a member of heat shock protein, is highly expressed by leukemia cells, and elicit humoral immune responses in leukemia patients, and it might be a potential target for antileukemia therapy and an antigen-specific immunotherapy for leukemia.

    DOI: 10.1016/j.exphem.2007.03.015

    Web of Science

    researchmap

  • Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Reviewed

    Masuko M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K, Aoki S, Fuse I, Kodama M, Furukawa T, Aizawa Y

    Internal medicine (Tokyo, Japan)   46 ( 9 )   551 - 555   2007

     More details

    Language:English   Publisher:The Japanese Society of Internal Medicine  

    <b>Objective:</b> Cardiovascular complication is one of the serious complications in stem cell transplantation (SCT). We measured plasma brain natriuretic peptide (BNP) concentrations in patients who received SCT to evaluate possible cardiac toxicity of the regimens employed in SCT.<br> <b>Patients:</b> Ten patients with allogeneic SCT and 5 patients with autologous SCT using myeloablative conditioning regimens were enrolled. The preparative chemotherapy for 8 patients with allogeneic SCT included cyclophosphamide (60 mg/kg i.v. for 2 days) and other drugs and that for autologous SCT included cyclophosphamide (50 mg/kg for 2 days) and other drugs. Total body irradiation (TBI) was employed only in the patients who received allogeneic SCT.<br> <b>Method:</b> Plasma BNP was measured using a radioimmunoassay for human BNP before and after SCT.<br> <b>Results:</b> In 13 of 15 patients, BNP levels were elevated after SCT. In patients who received a total body irradiation (TBI) of 13.2 Gy, BNP levels were higher than those without irradiation (p=0.01). The BNP level reached a peak within 6 months after SCT in most patients and fell thereafter. But 7 of the 15 patients (46.7%) had an abnormally high level of plasma BNP even after 6 months of SCT which suggests subclinical myocardial damage.<br> <b>Conclusion:</b> A rise in plasma BNP was frequently observed after SCT, and may be considered to represent cardiac damage caused by the preparative chemotherapy and/or total body irradiation. Since a rise was noted 6 months after SCT, long-term evaluation of cardiac function is important.<br>

    DOI: 10.2169/internalmedicine.46.6188

    PubMed

    CiNii Article

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007315596

  • Expression of BAFF-R (BR3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody Reviewed

    N Nakamura, H Hase, D Sakurai, S Yoshida, M Abe, N Tsukada, J Takizawa, S Aoki, M Kojima, S Nakamura, T Kobata

    VIRCHOWS ARCHIV   447 ( 1 )   53 - 60   2005.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    BAFF-receptor (BAFF-R) is required for the successful maturation and survival of B-cells. We developed an anti-human BAFF-R monoclonal antibody (mAb), 8A7. The reactivity of 8A7 in normal and neoplastic tissue was examined by performing immunohistochemistry on paraffin-embedded sections. 8A7 reacted with lymphocytes in the mantle and marginal zones, but not with lymphocytes in the interfollicular area. Lymphocytes in the germinal centers were found to be negative or occasionally weakly positive for 8A7. BAFF-R expression was found only in B-cell lymphoma (44/80, positive cases/examined cases): B-lymphoblastic lymphoma 0/3, B-chronic lymphocytic leukemia/small lymphocytic lymphoma 4/4, mantle cell lymphoma 9/11, follicular lymphoma 10/14, diffuse large B-cell lymphoma (DLBCL) 11/25, marginal zone B-cell lymphoma 8/10, lymphoplasmacytic lymphoma 2/2, plasma cell myeloma 0/2, and Burkitt lymphoma 0/9, but not in T/NK cell lymphomas (0/19) or Hodgkin lymphoma (0/10). BAFF-R was expressed in most low-grade B-cell neoplasms and a small number of DLBCL, suggesting that BAFF-R may play an important role in the proliferation of neoplastic lymphoid cells. Thus, the mAb is very useful for further understanding of both healthy B-cell biology and its pathogenic neoplasms.

    DOI: 10.1007/s00428-005-1275-6

    Web of Science

    researchmap

  • ATIII低下を伴うDICを合併したAPLの1例

    柴崎 康彦, 橋本 誠雄, 鳥羽 健, 柳川 貴央, 瀧澤 淳, 相澤 義房

    新潟医学会雑誌   116 ( 11 )   567 - 567   2002.11

  • IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy Reviewed

    G Hatzivassiliou, Miller, I, J Takizawa, N Palanisamy, PH Rao, S Iida, S Tagawa, M Taniwaki, J Russo, A Neri, G Cattoretti, R Clynes, C Mendelsohn, RSK Chaganti, R Dalla-Favera

    IMMUNITY   14 ( 3 )   277 - 289   2001.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CELL PRESS  

    Abnormalities of chromosome 1q21 are common in B cell malignancies, but their target genes are largely unknown. By cloning the breakpoints of a (1;14) (q21;q32) chromosomal translocation in a myeloma cell line, we have identified two novel genes, IRTA1 and IRTA2, encoding cell surface receptors homologous to the Fc and inhibitory receptor families. Both genes are selectively expressed in mature B cells: IRTA1 in marginal zone B cells and IRTA2 in centrocytes, marginal zone B cells, and immunoblasts. As a result of the t(1;14), IRTA1 is fused to the immunoglobulin C alpha domain to produce a chimeric IRTA1/C alpha fusion protein. In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis.

    DOI: 10.1016/S1074-7613(01)00109-1

    Web of Science

    PubMed

    researchmap

  • 5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: A case report Reviewed

    Hidenobu Takahashi, Tatsuo Furukawa, Shigeo Hashimoto, Naoko Kanazawa, Naoaki Satoh, Noriatsu Suzuki, Jun Takizawa, Yumiko Uesugi, Masuhiro Takahashi, Yoshifusa Aizawa, Tadashi Koike

    American Journal of Hematology   64 ( 2 )   120 - 123   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 28-year-old Japanese woman with suspected essential thrombocythemia (ET) had marked thrombocytosis, mild leukocytosis with normal neutrophil alkaline phosphatase activity, and no anemia. She was monitored without being given any medication. Eleven years later, complete blood counts showed no remarkable changes but some non-lobulated mononuclear megakaryocytes were found in the bone marrow. Cytogenetic analysis revealed deletion of the long arm of chromosome 5 (5q-). Subsequently, hemoglobin and platelet counts decreased gradually, splenomegaly appeared and progressed, after which myelofibrosis developed. Acute leukemia developed 16 years after the first documentation of thrombocytosis. 5q- syndrome is known to be a myelodysplastic syndrome (MDS) with unique clinical features and cases with this syndrome presenting with thrombocytosis of more than 1,000 x 109/L but without anemia are rare. Furthermore, it is noteworthy that in this patient transition to acute leukemia occurred following development of myelofibrosis and marked splenomegaly, which are generally observed in blastic crises resulting from chronic myeloproliferative disorders (CMPD). The patient showed features indicative of CMPD rather than of MDS in spite of presenting with 5q- chromosomal abnormality. This case supports the concept of 'mixed myelodysplastic and myeloproliferative syndromes' and suggests the possibility of the appearance of CMPD-like manifestations in 5q- syndrome. (C) 2000 Wiley-Liss, Inc.

    DOI: 10.1002/(SICI)1096-8652(200006)64:2<120::AID-AJH9>3.0.CO;2-M

    Scopus

    PubMed

    researchmap

  • The TCL1 oncogene is not overexpressed in patients with adult T cell leukemia Reviewed

    J Takizawa, M Seto

    LEUKEMIA   13 ( 2 )   314 - 314   1999.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:STOCKTON PRESS  

    DOI: 10.1038/sj.leu.2401267

    Web of Science

    PubMed

    researchmap

  • Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia Reviewed

    J Takizawa, R Suzuki, H Kuroda, A Utsunomiya, Y Kagami, T Joh, Y Aizawa, R Ueda, M Seto

    JAPANESE JOURNAL OF CANCER RESEARCH   89 ( 7 )   712 - 718   1998.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCI IRELAND LTD  

    The TCL1 gene was recently cloned as a candidate target within the 14q32.1 breakpoint cluster region observed in T-cell malignancies. We examined the TCL1 gene expression in 21 patients with adult T-cell leukemia (ATL) and 5 cell Lines, because ATL is reported to have frequent chromosome 14 band (q32 aberrations, However, 20 of the ATL patients and all 5 cell lines lacked any TCL1 expression on northern blot analysis, and TCL1 transcripts were only very faintly detected in the remaining one patient, Expansion of our analysis to include other types of hematopoietic malignancies revealed strong expression of the TCL1 gene in almost all tumor cells of B-cell lineage except myelomas. However no TCL1 signals were encountered in cells of T-cell or myeloid lineages. In normal human tissues TCL1 was found to be expressed in the spleen. lymph nodes and B-lymphocytes of peripheral blood. These results indicate that TCL1 is not a major target gene for ATL, but that it may play a role in B-cell differentiation and proliferation.

    DOI: 10.1111/j.1349-7006.1998.tb03275.x

    Web of Science

    PubMed

    researchmap

  • Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation Reviewed

    Tatsuroh Joh, Yoshitoyo Kagami, Kazuhito Yamamoto, Tatsuya Segawa, Jun Takizawa, Toshitada Takahashi, Ryuzo Ueda, Masao Seto

    Oncogene   13 ( 9 )   1945 - 1953   1996

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    11q23 chromosome aberrations are frequently observed in infantile as well as therapy-related leukemias. The target gene at 11q23, MLL, is disrupted by the translocation and becomes fused to various translocation partner genes such as AF4/FEL, LTG9/AF9 and LTG19/ENL. The resulting chimeric mRNAs are fused in frame and have been predicted to encode leukemia-specific chimeric proteins. In the present study, we raised antibodies against MLL, LTG9 and LTG19 and demonstrated that MLL and chimeric MLL-LTG9 and MLL-LTG19 products are synthesized in vivo and are localized in the nuclei, using immunofluorescence and cell fractionation studies. The truncated N-terminal portion of the MLL product common to the various types of 11q23 translocation was also localized in the nuclei in a similar fashion. Murine 32Dc13 cells stably expressing the truncated N-terminal MLL protein exhibited an inhibition of differentiation and a growth advantage following stimulation by granulocyte-colony stimulating factor, although the IL-3 dependency was not significantly changed in comparison to the parental cells. These results suggest that the N-terminal portion common to various MLL-chimeric products plays an important role in leukemogenesis.

    Scopus

    PubMed

    researchmap

  • Allogenic Bone Marrow Transplantation for Fanconi's Anemia with Leukemic Transformation from and Hla Identical Father Reviewed

    TAKIZAWA Jun, KISHI Kenji, MORIYAMA Yoshiaki, HASHIMOTO Shigeo, GOTOH Takao, HIGUCHI Wataru, WADA Ken, NARITA Miwako, AOKI Sadao, TAKAHASHI Masuhiro, KOIKE Tadashi, SHIBATA Akira

    Rinsho Ketsueki   36 ( 6 )   615 - 620   1995.6

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Hematology  

    We report a case of a 19-year-old male with congenital aplastic anemia and multiple abnormalities; short stature, hypoplastic thumb, skin pigmentation and mental retardation. He was admitted to our hospital because of severe pancytopenia. Bone marrow aspiration showed markedly hypocellular marrow with 42% myeloblasts. He was diagnosed as AML (M2) transformed from Fanconi's anemia and underwent allo-BMT from an HLA-identical father. The conditioning regimen consisted of high dose Ara-C, high dose etoposide and 12Gy fractionated total body irradiation. Severe toxicity associated with the conditioning regimen was not observed. Ciclosporin A and short-term methotrexate were administered for prophylaxis of acute GVHD. Neither acute nor chronic GVHD were observed. He is well and free of disease for 15 months since BMT. Very few cases of Fanconi's anemia with leukemic transformation treated by BMT have been reported. Long-term observation will be necessary to evaluate our conditioning regimen for Fanconi's anemia with leukemic transformation.

    DOI: 10.11406/rinketsu.36.615

    CiNii Article

    CiNii Books

    researchmap

▶ display all

Books

  • 新臨床腫瘍学 : がん薬物療法専門医のために

    日本臨床腫瘍学会( Role: Contributor ,  43 造血・リンパ組織の腫瘍 5. 慢性リンパ性白血病(CLL)と類縁疾患)

    南江堂  2021.5  ( ISBN:9784524227396

     More details

    Total pages:xix, 757p   Language:Japanese

    CiNii Books

    researchmap

  • 悪性リンパ腫治療マニュアル

    永井, 宏和, 山口, 素子, 丸山, 大, 飛内, 賢正, 木下, 朝博, 塚崎, 邦弘( Role: Contributor ,  第Ⅲ章 悪性リンパ腫-治療の実際 1. 病型別治療方針 C. 慢性リンパ性白血病/小リンパ球性リンパ腫)

    南江堂  2020.11  ( ISBN:9784524226450

     More details

    Total pages:x, 395p   Language:Japanese

    CiNii Books

    researchmap

  • 今日の治療指針 2020年版 : 私はこう治療している

    福井次矢, 高木誠, 小室一成( Role: Contributor ,  慢性リンパ性白血病)

    医学書院  2020.1 

     More details

    Total pages:冊   Language:Japanese

    researchmap

  • 血液専門医テキスト

    日本血液学会( Role: Contributor ,  第Ⅸ章 白血球系疾患:腫瘍性疾患 15.慢性リンパ性白血病とその類縁疾患)

    南江堂  2019.10  ( ISBN:9784524248827

     More details

    Total pages:xix, 635p   Language:Japanese

    CiNii Books

    researchmap

  • Molecular Targeted Therapy for DLBCL. Primary Central Nervous System Lymphoma (PCNSL)

    Kawamoto K, Takizawa J( Role: Contributor ,  Molecular Targeted Therapy for DLBCL.)

    Nova science publishers  2016.7  ( ISBN:9781634853224

     More details

    Responsible for pages:189-200   Language:English Book type:Scholarly book

    researchmap

  • 危機管理について 大学病院などの再生医療を支える細胞プロセッシング室運営マニュアル

    瀧澤 淳( Role: Sole author)

    ウイネット出版/星雲社  2012 

     More details

    Language:Japanese Book type:Scholarly book

    researchmap

  • 既治療のハイリスク染色体を有するCLLに対するacalabrutinibとibrutinibのランダム化第Ⅲ相試験(ELEVATE-RR).

    瀧澤淳

    科学評論社  2022.6 

     More details

  • 特集 慢性白血病-最新の診断と治療- Ⅳ. 慢性白血病の予後予測因子.慢性リンパ性白血病とその類縁疾患の予後予測因子.

    瀧澤 淳

    2021.11 

     More details

  • EBM血液疾患の治療2021-2022

    木崎, 昌弘, 鈴木, 律朗, 神田, 善伸, 大森, 司, 金倉, 譲, 山﨑, 宏人( Role: Contributor ,  再発・再燃びまん性大細胞型B細胞リンパ腫(DLBCL)の治療方針)

    中外医学社  2021.1  ( ISBN:9784498225244

     More details

    Total pages:iv, 637p   Language:Japanese

    CiNii Books

    researchmap

  • 今日の治療指針 2021年版 : 私はこう治療している

    福井, 次矢, 高木, 誠, 小室, 一成, 赤司, 浩一(大学教員)( Role: Contributor ,  顆粒球減少症(無顆粒球症))

    医学書院  2021.1  ( ISBN:9784260042833

     More details

    Total pages:59, 2151p   Language:Japanese

    CiNii Books

    researchmap

  • 造血器腫瘍学(第2 版) 基礎と臨床の最新研究動向

    瀧澤 淳( Role: Contributor ,  V.リンパ系腫瘍の臨床 慢性リンパ性白血病および類縁疾患の病因・病態と治療)

    日本臨牀社  2020.8 

     More details

  • EBM血液疾患の治療2019-2020

    金倉, 譲, 木崎, 昌弘, 鈴木, 律朗, 神田, 善伸( Role: Contributor ,  若年者マントル細胞リンパ腫の治療方針)

    中外医学社  2018.10  ( ISBN:4498125126

     More details

    Total pages:冊   Language:Japanese

    CiNii Books

    researchmap

  • 節外性NK/T細胞リンパ腫の治療 EBM 血液疾患の治療2017-2018

    瀧澤 淳( Role: Contributor ,  節外性NK/T細胞リンパ腫の治療)

    中外医学社  2016.10  ( ISBN:9784498225022

     More details

    Responsible for pages:291-297   Language:Japanese Book type:Scholarly book

    researchmap

  • 血液疾患の新規治療薬2016 イブルチニブ

    瀧澤 淳( Role: Contributor ,  イブルチニブ)

    毘沙門堂  2016.9  ( ISBN:9784907524067

     More details

    Total pages:56   Responsible for pages:8-10   Language:Japanese Book type:Scholarly book

    researchmap

  • 眼・眼付属器リンパ腫 節外リンパ腫の臓器別特徴と治療 リンパ腫学-最新の研究動向-

    瀧澤 淳, 尾山 徳秀( Role: Contributor ,  節外リンパ腫の臓器別特徴と治療 眼・眼付属器リンパ腫)

    日本臨牀社  2015.10 

     More details

    Total pages:695   Responsible for pages:614-618   Language:Japanese Book type:Scholarly book

    researchmap

  • 初発CLLの治療方針 EBM 血液疾患の治療2015-2016

    瀧澤 淳( Role: Sole author)

    中外医学社  2014 

     More details

    Language:Japanese Book type:Scholarly book

    researchmap

  • 慢性リンパ性白血病 今日の治療指針2013年版

    瀧澤 淳( Role: Sole author)

    医学書院  2013 

     More details

    Language:Japanese Book type:Scholarly book

    researchmap

  • 慢性関節リウマチに対するTNF阻害剤はリンパ腫の発症リスクを高めるか? EBM 血液疾患の治療

    瀧澤 淳( Role: Sole author)

    中外医学社  2012 

     More details

    Language:Japanese Book type:Scholarly book

    researchmap

  • Burkittリンパ腫とびまん性大細胞型B細胞リンパ腫の鑑別方法とその治療 臨床 症例検討を通して学ぶ悪性リンパ腫診療の実際-リンフォーマ井戸端会議から学んだこと-

    瀧澤 淳, 青木定夫( Role: Joint author)

    メディカルレビュー社  2010 

     More details

    Language:Japanese Book type:Scholarly book

    researchmap

  • 多発性骨髄腫診療ハンドブック

    瀧澤 淳, 他, 飯( Role: Joint author)

    中外医学社  2008.10 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

    researchmap

  • カラーテキスト血液病学

    瀧澤 淳, 青木定夫( Role: Joint author)

    中外医学社  2007.10 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

    researchmap

  • 慢性リンパ性白血病とその類縁疾患の予後予測因子. 特集 慢性白血病-最新の診断と治療- Ⅳ. 慢性白血病の予後予測因子

    瀧澤淳

    日本臨牀社 

     More details

▶ display all

MISC

  • 単一施設における末梢性T細胞リンパ腫、非特定型の後方視的解析

    鈴木 隆晴, 河本 啓介, 田村 秀, 上村 駿, 海發 茜, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   58 ( 8 )   905 - 911   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    1998年から2015年までに新潟大学医歯学総合病院血液内科で診断したPTCL,NOS 28例について臨床像,病理学的特徴,治療内容,予後を後方視的に解析した。性別は男性16例,女性12例で年齢中央値62.5(26〜88)歳。IPIはHIが10例,Hが9例であり高リスク群が68%を占めていた。初回治療としてCHOPまたはTHP-COP療法が12例に行われ,第三世代化学療法が9例に行われた。予後の確認ができた26例の観察期間中央値30ヵ月(範囲1〜164ヵ月)における2年OSは61%,2年PFSは44%であった。初回治療における効果がCRであった11例は5年OS 83%,5年PFS 75%であり,CRに至らなかった9例に比べ予後良好であった(p&lt;0.005)。PTCL,NOSに対する新規薬剤を用いた治療法の開発が望まれる。(著者抄録)

    researchmap

  • Chronic lymphocytic leukemia: pathophysiology and current therapy Invited Reviewed

    TAKIZAWA Jun

    Rinsho Ketsueki   58 ( 5 )   471 - 479   2017.5

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:The Japanese Society of Hematology  

    <p>Chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in western countries, but it is rare in Japan. Several mutations have been identified in patients with CLL using next-generation sequencing, but disease-specific mutations were not found. Some mutations, such as those in <i>TP53</i>, <i>NOTCH1</i>, <i>SF3B</i>, and <i>BIRC3</i> are useful for risk stratification and prognosis prediction in patients with CLL. Strategies for treating CLL are rapidly evolving, with targeted agents such as the B-cell receptor signaling pathway inhibitors (ibrutinib, idelalisib), novel anti-CD20 monoclonal antibody (obinutuzumab), and Bcl-2 inhibitor (venetoclax) being approved by the US Food and Drug Administration. Although key drugs such as chlorambucil and rituximab cannot be used in Japan, others such as ibrutinib and bendamustine were recently approved for CLL treatment in Japan.</p>

    DOI: 10.11406/rinketsu.58.471

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2017277000

  • MALTリンパ腫65例の臨床病理学的検討

    瀧澤 淳, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 成田 美和子, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 青木 定夫, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   54   101 - 101   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • CPC: A case of subacute progressive focal neurological symptoms with renal infarction.

    長谷川絵理子, 岩渕洋平, 下島恭弘, 田澤浩一, 和田庸子, 金澤雅人, 小林大介, 柿田明美, 瀧澤淳, 鋪野紀好, 松本正孝, 須永眞司

    日本内科学会雑誌   111 ( 9 )   1969 - 1985   2022.9

     More details

  • 薬剤性過敏症症候群(DIHS)様症状で発症した血管免疫芽球性T細胞リンパ腫(AITL)の1例

    内田 梢太, 長谷川 瑛人, 寺尾 香菜, 武居 慎吾, 佐藤 亜美, 阿部 理一郎, 吉澤 優太, 諏訪部 達也, 瀧澤 淳, 笠井 昭男

    日本皮膚科学会雑誌   132 ( 6 )   1490 - 1490   2022.5

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    J-GLOBAL

    researchmap

  • Two cases of refractory pleural effusion after allo-HSCT successfully treated with ibrutinib

    片桐隆幸, 古山悠里, 川上絢子, 武田ルイ, 米沢穂高, 諏訪部達也, 布施香子, 布施香子, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義, 増子正義

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • Association between acute graft-versus-host disease and immune peptidome of HLA-B

    布施香子, 諏訪部達也, 片桐隆幸, 柴崎康彦, 瀧澤淳, 増子正義, 曽根博仁

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

  • 当初薬剤性過敏症症候群と診断された血管免疫芽球性T細胞リンパ腫の1例

    内田 梢太, 長谷川 瑛人, 平山 香菜, 武居 慎吾, 佐藤 亜美, 吉澤 優太, 諏訪部 達也, 瀧澤 淳, 笠井 昭男, 阿部 理一郎

    日本皮膚科学会雑誌   131 ( 5 )   1364 - 1364   2021.5

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    researchmap

  • AML with Major & minor-bcr/abl co-expressing clone after second hematopoietic cell transplants

    本宮奈津子, 本宮奈津子, 片桐隆幸, 武田ルイ, 水戸部正樹, 米沢穂高, 諏訪部達也, 布施香子, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

  • MDS/AML-MRC as a poor risk factor for primary graft failure in allogeneic hematopoietic cell transplantation

    田村秀, 柴崎康彦, 米沢穂高, 鈴木隆晴, 笠見卓哉, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • Successful treatment for MDS-EB2 using ATG for GVHD prophylaxis in allogenic BMT from HLA two loci mismatch unrelated donor

    米沢穂高, 柴崎康彦, 笠見卓哉, 鈴木隆晴, 田村秀, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • A case of MDS with graft failure in HLA 1 locus-mismatch rPBSCT after graft failure in HLA-matched urBMT

    笠見卓哉, 柴崎康彦, 米沢穂高, 田村秀, 鈴木隆晴, 河本啓介, 布施香子, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   60 ( 10 )   1503 - 1503   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Hodgkin lymphomaとAnaplastic large cell lymphomaの鑑別が困難であった巨大縦隔腫瘤を呈した1例

    河本 啓介, 鈴木 隆晴, 海發 茜, 田村 秀, 片桐 隆之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   59   133 - 133   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 日本では未分類である脾臓B細胞リンパ腫/白血病におけるBRAF遺伝子変異の分析(Analysis of BRAF mutation in splenic B-cell lymphoma/leukemia, unclassifiable in Japan)

    鈴木 隆晴, 三好 寛明, 河本 啓介, 荒川 文子, 古田 拓也, 下埜 城嗣, 山田 恭平, 柳田 恵理子, 瀬戸 加大, 曽根 博仁, 瀧澤 淳, 大島 孝一

    日本リンパ網内系学会会誌   59   145 - 145   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 3度目の同種造血細胞移植後ポナチニブ維持療法を行い,寛解を維持している再発・難治Ph陽性ALL

    海發茜, 柴崎康彦, 諏訪部達也, 笠見卓哉, 田村秀, 片桐隆幸, 河本啓介, 難波亜矢子, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   173   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 非寛解期末梢血幹細胞移植後に通常量5‐AZA療法を施行し,寛解を維持しているEVI‐1陽性AMLの一例

    田村秀, 柴崎康彦, 上村駿, 笠見卓哉, 海發茜, 今西明, 片桐隆幸, 難波亜矢子, 河本啓介, 牛木隆志, 布施香子, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   296   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 抗原特異的細胞障害性T細胞の増幅に及ぼすIMidの効果の検討

    小川彩空, 諏訪部達也, 柴崎康裕, 後藤若奈, 増子正義, 内山孝由, 瀧澤淳, 曽根博仁, 高橋益廣, 成田美和子

    日本免疫治療学会学術集会プログラム・抄録集   16th   2019

  • ATRA・ATO併用療法により寛解を維持している再発性治療関連急性前骨髄白血病の1例

    前田 愁一郎, 布施 香子, 諏訪部 達也, 笠見 卓哉, 河本 啓介, 田中 智之, 難波 亜矢子, 小林 弘典, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 11 )   2496 - 2496   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • ATRA・ATO併用療法により寛解を維持している再発性治療関連急性前骨髄白血病の1例

    前田 愁一郎, 布施 香子, 諏訪部 達也, 笠見 卓哉, 河本 啓介, 田中 智之, 難波 亜矢子, 小林 弘典, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 11 )   2496 - 2496   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1678 - 1678   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 濾胞性リンパ腫初回診断時におけるアグレッシブリンパ腫への形質転換予測(MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma)

    桐生 真依子, 河本 啓介, 鈴木 隆晴, 田村 秀, 上村 駿, 海發 茜, 諏訪部 達也, 今西 明, 笠見 卓哉, 根本 洋樹, 片桐 隆幸, 田中 智之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 瀬戸 加大, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 9 )   1593 - 1593   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1678 - 1678   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 濾胞性リンパ腫初回診断時におけるアグレッシブリンパ腫への形質転換予測(MYC copy number predicts histologic transformation of follicular lymphoma to aggressive lymphoma)

    桐生 真依子, 河本 啓介, 鈴木 隆晴, 田村 秀, 上村 駿, 海發 茜, 諏訪部 達也, 今西 明, 笠見 卓哉, 根本 洋樹, 片桐 隆幸, 田中 智之, 難波 亜矢子, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 瀬戸 加大, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 9 )   1593 - 1593   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • GDP療法がtriple-hit lymphomaの救援療法として有効であった1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 田村 秀, 小堺 貴司, 難波 亜矢子, 諏訪部 達也, 笠見 卓哉, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   59 ( 5 )   620 - 621   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 再発性/難治性DLBCL患者におけるifosfamide、etoposide、dexamethasone、中程度用量cytarabineを併用したrituximab(R-IDEA)療法に関する第II相研究(A phase II study of rituximab plus ifosfamide, etoposide, dexamethasone and intermediate dose cytarabine(R-IDEA) in patients with relapsed/refractory DL

    前田 嘉信, 近藤 英生, 山本 和彦, 増成 太郎, 三浦 勝浩, 瀧澤 淳, 正木 康史, 村上 純, 富田 直人, 神野 正敏

    日本リンパ網内系学会会誌   58   115 - 115   2018.5

     More details

    Language:English   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • ビタミンD3産生性と考えられるALK陰性未分化大細胞リンパ腫の1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 難波 亜矢子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   121 - 121   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • G-CSFを産生し初回治療中に再発したびまん性大細胞型B細胞性リンパ腫の1例

    笠見 卓哉, 河本 啓介, 鈴木 隆晴, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   114 - 114   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • ビタミンD3産生性と考えられるALK陰性未分化大細胞リンパ腫の1例

    水戸部 正樹, 河本 啓介, 鈴木 隆晴, 難波 亜矢子, 柴崎 康彦, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   121 - 121   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • G-CSFを産生し初回治療中に再発したびまん性大細胞型B細胞性リンパ腫の1例

    笠見 卓哉, 河本 啓介, 鈴木 隆晴, 田中 智之, 布施 香子, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   58   114 - 114   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Antigen specific INF-γproduction of the amplified CTL using plasmacytoid dendritic cell line (PMDC11)

    Yamada Syunya, Goto Wakana, Ogawa Sara, Masuko Masayoshi, Kobayashi Kaho, Shibasaki Yasuhiko, Uchiyama Takayoshi, Takizawa Jun, Sone Hirohito, Takahashi Masuhiro, Narita Miwako

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   15 ( 1 )   9 - 17   2018.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    It is becoming clear that antigen-specific cytotoxic T cells (CTLs) play an important role in anti-tumor immune system due to the recent confirmation of clinical effects of immune-checkpoint inhibitors. We tried to amplify efficiently WT1 specific oligoclonal CTLs from the peripheral blood of the case treated with WT1 peptide vaccine using dendritic cell line PMDC 11 which was established in our laboratory. Antigen - specific IFN - γ - producing ability was confirmed in the amplified WT1- specific CTLs. This result means that the antigen - specific CTLs amplified by PMDC 11 maintain cytotoxic ability against to tumor specific antigen. This method of amplifying antigen-specific CTLs using MLPC and PMDC 11 will lead to application of CTL to clinical application and TCR and surface antigen analysis.

    CiNii Article

    researchmap

  • 慢性リンパ性白血病(CLL)と類縁疾患の鑑別診断 Invited

    瀧澤 淳, 桐生 真依子, 河本 啓介

    血液フロンティア   28 ( 2 )   179 - 185   2018.1

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher:医薬ジャーナル社  

    DOI: 10.20837/5201802179

    researchmap

  • 多職種連携チーム医療が著効した食道慢性GVHDの一例

    難波亜矢子, 上村駿, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 田中智之, 小林弘典, 布施香子, 小師優子, 真柄仁, 高昌良, 冨永顕太郎, 橋本哲, 横山純二, 柴崎康彦, 柴崎康彦, 瀧澤淳, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   305   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • マーカー染色体が急性骨髄性白血病に対する同種造血細胞移植成績に与える影響

    田中智之, 布施香子, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 牛木隆志, 森山雅人, 柴崎康彦, 柴崎康彦, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   239   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 血小板凝集能低下により止血が困難であった骨髄異形成症候群

    田中 智之, 小堺 貴司, 北嶋 俊樹, 布施 香子, 小林 弘典, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 曽根 博仁, 布施 一郎, 増子 正義

    臨床血液   58 ( 12 )   2402 - 2405   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は75歳の女性。血液検査で貧血と末梢血に芽球を認められたため、当院を紹介受診した。骨髄穿刺で骨髄異形成症候群(myelodysplastic syndrome with excess blasts 2, MDS-EB-2)と診断された。血球減少の進行や芽球の増加、および出血症状はなく経過していた。診断から10ヵ月後、左手母指球に外傷を負い、内出血が持続し、止血困難となったため緊急入院した。血小板数は正常範囲であったが、血小板機能検査でコラーゲン凝集能とアラキドン酸凝集能の低下を認められた。抗血小板薬の内服はなく、またこれまで出血傾向の既往もなかったことから、MDSによる二次性の血小板機能低下による出血と判断し、血小板輸血を行い止血した。MDSの患者では、潜在的に血小板凝集能が低下していることが多く、血小板数の割に出血傾向が強い場合には血小板凝集能を調べ、血小板輸血などの治療介入を検討する必要がある。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J01540&link_issn=&doc_id=20180112380008&doc_link_id=130006308822&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130006308822&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • HLA半合致移植後AMLとして再発したB-ALLの1例

    小堺 貴司, 田村 秀, 布施 香子, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 増子 正義

    臨床血液   58 ( 11 )   2270 - 2271   2017.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 4 当科におけるMTX関連リンパ増殖性疾患の後方視的解析 (Ⅰ.一般演題, 第104回膠原病研究会)

    131 ( 10 )   618 - 618   2017.10

     More details

  • 臍帯血移植後にヒトパルボウイルスB19感染による自己免疫性溶血性貧血と赤芽球癆を発症した1例

    海發 茜, 柴崎 康彦, 上村 駿, 田村 秀, 小堺 貴司, 難波 亜矢子, 小林 弘典, 布施 香子, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 8 )   1078 - 1078   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 顆粒球肉腫におけるPD-1/PD-L1発現の臨床病理学的検討

    河本 啓介, 三好 寛明, 喜安 純一, 佐々木 裕哉, 栗田 大輔, 鈴木 隆晴, 曽根 博仁, 瀬戸 加大, 瀧澤 淳, 大島 孝一

    日本リンパ網内系学会会誌   57   90 - 90   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 顆粒球肉腫におけるPD-1/PD-L1発現の臨床病理学的検討

    河本 啓介, 三好 寛明, 喜安 純一, 佐々木 裕哉, 栗田 大輔, 鈴木 隆晴, 曽根 博仁, 瀬戸 加大, 瀧澤 淳, 大島 孝一

    日本リンパ網内系学会会誌   57   108 - 108   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 樹木構造接近法を用いた急性白血病,骨髄異形成症候群に対する造血細胞移植後の予後因子の解析

    布施香子, 上村駿, 海發茜, 鈴木隆晴, 田村秀, 片桐隆幸, 根本洋樹, 小林弘典, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   247   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 移植後長期フォローアップにおける再発の早期発見を目的とした末梢血STR法の有用性

    海發茜, 柴崎康彦, 中村岳史, 椎谷恵子, 和田玲子, 田村秀, 鈴木隆晴, 上村駿, 片桐隆幸, 根元洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   252   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植において生着後早期の免疫再構築はドナーソースや移植法により異なる

    上村駿, 柴崎康彦, 片桐隆幸, 井藤ヒロミ, 海發茜, 田村秀, 鈴木隆晴, 根本洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   237   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 破壊性甲状腺炎をともなったMYC転座陽性甲状腺悪性リンパ腫の1例

    山田 貴穂, 布施 香子, 柴崎 康彦, 河本 啓介, 羽入 修, 瀧澤 淳, 大島 孝一, 曽根 博仁

    日本内分泌学会雑誌   92 ( 3 )   635 - 635   2017.1

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • 抗CCR4抗体併用化学療法による寛解後の臍帯血移植が奏効した成人T細胞白血病リンパ腫

    諏訪部 達也, 柴崎 康彦, 海發 茜, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 1 )   32 - 36   2017.1

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は成人T細胞白血病/リンパ腫(ATLL)急性型の62歳男性。CHOP療法単独では治療抵抗性であったが,抗CCR4抗体mogamulizumab併用CHOP療法が奏効し寛解を得た。HLA一致血縁・非血縁ドナーが得られず,mogamulizumab最終投与後71日目に骨髄非破壊的前処置を用いた臍帯血移植を施行した。急性移植片対宿主病(GVHD)grade II(皮膚stage2)を発症したが,methylprednisolone投与により制御可能であり,移植後9ヵ月時点まで寛解を維持している。経過中,制御性T細胞(Treg)は著減したままの状態であった。同種造血幹細胞移植はATLLの根治的治療であるが,移植前にmogamulizumabを使用する際,Tregの減少による急性GVHDの発症頻度・重症度が増加する可能性が報告されている。寛解期移植を目指すためにmogamulizumabを使用せざるを得ない症例における至適なドナーソースや移植時期,GVHD予防法に関して,更なる症例の蓄積が望まれる。(著者抄録)

    researchmap

  • Comparative Analysis of Japanese and European Typical CLL Patients

    Jun Takizawa, Michaela Gruber, Ritsuro Suzuki, Naoya Nakamura, Gregor Hoermann, Leonhard Muellauer, Sadao Aoki, Junji Suzumiya, Ulrich Jaeger

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • HLA半合致移植を施行した最重症再生不良性貧血の1例

    宮腰 淑子, 柴崎 康彦, 諏訪部 達也, 片桐 隆幸, 小林 弘典, 布施 香子, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 11 )   2416 - 2416   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • HLA半合致移植を施行した最重症再生不良性貧血の1例

    宮腰 淑子, 柴崎 康彦, 諏訪部 達也, 片桐 隆幸, 小林 弘典, 布施 香子, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 11 )   2416 - 2416   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 多発血栓を来したTAFRO症候群の1例

    上村 駿, 小林 弘典, 田村 秀, 鈴木 隆晴, 海發 茜, 河本 啓介, 笠見 卓哉, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2423 - 2423   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 多発血栓を来したTAFRO症候群の1例

    上村 駿, 小林 弘典, 田村 秀, 鈴木 隆晴, 海發 茜, 河本 啓介, 笠見 卓哉, 根本 洋樹, 布施 香子, 柴崎 康彦, 増子 正義, 曽根 博仁, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2423 - 2423   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 当科におけるIVLBCL 14例の臨床病理学的検討

    諏訪部 達也, 河本 啓介, 片桐 隆幸, 宮腰 淑子, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   56   92 - 92   2016.8

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • PCNSL寛解後12年を経て発症した副鼻腔DLBCLで、繰り返す皮膚再発に対して少量経口エトポシド療法が有効であった1症例

    田村 秀, 大橋 瑠子, 梅津 哉, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 宮腰 淑子, 北嶋 俊樹, 柴崎 康彦, 曽根 博仁, 青木 洋, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   56   98 - 98   2016.8

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 抗CCR4抗体併用化学療法により寛解が得られた後に、臍帯血移植を行ったATLLの1例

    諏訪部 達也, 柴崎 康彦, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 6 )   776 - 776   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE OF ADVANCED STAGE: NKEA (NEXT-GENERATION THERAPY FOR NK/T-CELL LYMPHOMA IN EAST ASIA) PROJECT

    R. Suzuki, M. Yamaguchi, M. Oguchi, N. Asano, N. Tomita, J. Amaki, T. Ando, N. Niitsu, N. Sekiguchi, J. Takizawa, K. Miyazaki, N. Katayama

    HAEMATOLOGICA   101   388 - 389   2016.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • アルブミン,フェリチン,CRPを用いたBiomarker indexは,造血幹細胞移植前患者に対するHCT‐CIとは独立した予後予測因子である

    諏訪部達也, 柴崎康彦, 宮腰淑子, 布施香子, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   38th   221   2016.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Combination of Low Rate of gamma delta T Cells and High Rate of Regulatory T Cells after Allogeneic Stem Cell Transplantation Is a Poor Prognostic Factor for Patients with Hematological Neoplasm

    Yasuhiko Shibasaki, Syukuko Miyakoshi, Takayuki Katagiri, Kyoko Fuse, Hironori Kobayashi, Takashi Ushiki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • The Sil Index Is a Useful Prognostic Indicator for Diffuse Large B-Cell Lymphoma

    Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP

    Katsuhiro Miura, Jun Konishi, Takaaki Miyake, Makita Masanori, Atsuko Hojo, Yasufumi Masaki, Masatoshi Uno, Jun Ozaki, Chikamasa Yoshida, Daigo Niiya, Koichi Kitazume, Yoshinobu Maeda, Jun Takizawa, Rika Sakai, Yuichiro Nawa, Tomofumi Yano, Kazuhiko Yamamoto, Kazutaka Sunami, Yasushi Hiramatsu, Kazutoshi Aoyama, Hideki Tsujimura, Yoshihiro Hatta, Masatoshi Kanno

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 脳死両肺移植後の小腸DLBCL発症に対して化学療法施行後に気管支アスペルギローシスを発症した1例

    河本 啓介, 佐藤 征二郎, 根本 洋樹, 小林 弘典, 柴崎 康彦, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 土田 正則, 曽根 博仁, 増子 正義

    臨床血液   56 ( 11 )   2361 - 2361   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Malignant Lymphoma : Recent progress in Diagnosis and Treatment

    Takizawa Jun

    129 ( 10 )   557 - 561   2015.10

  • The usage of T cell receptor β-chain variable region of WT1 specific Cytotoxic T lymphocytes in CML patient treated WT1 peptide vaccination

    12 ( 1 )   83 - 89   2015.9

  • The characteristic of chronic lymphocytic leukemia in Japan: An interim result of CLLRSG-01 study

    Jun Takizawa, Junji Suzumiya, Ritsuro Suzuki, Toru Kiguchi, Koji Izutsu, Hideki Asaoku, Yoshio Saburi, Taro Masunari, Atae Utsunomiya, Naoya Nakamura, Koichi Ohshima, Sadao Aoki

    LEUKEMIA & LYMPHOMA   56   39 - +   2015.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:TAYLOR & FRANCIS LTD  

    Web of Science

    researchmap

  • 再発・難治性縦隔原発大細胞型B細胞リンパ腫に対する自家造血幹細胞移植併用大量化学療法の有効性の解析:縦隔原発大細胞型B細胞リンパ腫多施設共同後方視的研究のサブグループ解析

    青木智広, 島田和之, 鈴木律朗, 伊豆津宏二, 前田嘉信, 瀧澤淳, 三谷絹子, 五十嵐忠彦, 酒井香生子, 宮崎香奈, 三原圭一朗, 高崎啓孝, 中村直哉, 冨田章裕, 清井仁, 中村栄男, 木下朝博, 小椋美知則

    日本リンパ網内系学会会誌   55   91 - 91   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    J-GLOBAL

    researchmap

  • MYC転座とBCL2転座を認めたCD20陰性EBV陽性胃原発B細胞リンパ腫の一例

    笠見 卓哉, 根本 洋樹, 片桐 隆幸, 河本 啓介, 小林 弘典, 柴崎 康彦, 増子 正義, 丸田 美和子, 曽根 博仁, 瀧澤 淳, 橋口 俊洋, 栗田 大輔, 大島 孝一

    日本リンパ網内系学会会誌   55   106 - 106   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 再発時CCND1転座陽性となったCD5陽性MALTリンパ腫の1例

    根本 洋樹, 笠見 卓哉, 片桐 隆幸, 河本 啓介, 小林 弘典, 牛木 隆志, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 竹内 賢吾, 中村 直哉, 栗田 大輔, 市川 理子, 大島 孝一

    日本リンパ網内系学会会誌   55   104 - 104   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • EBV関連疾患寛解後の全血EBV-DNA定量の再発予測の有用性に関する検討

    河本 啓介, 根本 洋樹, 笠見 卓哉, 片桐 隆幸, 小林 弘典, 柴崎 康彦, 増子 正義, 成田 美和子, 曽根 博仁, 大島 孝一, 瀧澤 淳

    日本リンパ網内系学会会誌   55   107 - 107   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • PERIPHERAL BLOOD EOSINOPHIL COUNT AT DAY 28 AS A PROGNOSTIC INDICATOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

    K. Kawamoto, Y. Shibasaki, H. Kobayashi, T. Ushiki, N. Sato, T. Yano, M. Moriyama, T. Kuroha, J. Takizawa, S. Hashimoto, M. Narita, T. Furukawa, H. Sone, M. Masuko

    HAEMATOLOGICA   100   280 - 280   2015.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • USEFULNESS OF DUAL-ENERGY CT FOR DETECTION OF LIVER IRON DEPOSITION IN TRANSFUSION-DEPENDENT PATIENTS

    H. Kobayashi, N. Yoshimura, T. Kasami, T. Katagiri, H. Nemoto, K. Kawamoto, T. Ushiki, Y. Shibasaki, M. Moriyama, J. Takizawa, M. Narita, H. Sone, M. Masuko

    HAEMATOLOGICA   100   789 - 789   2015.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • CHROMOSOMAL ABERRATIONS BY FLUORESCENCE IN SITU HYBRIDIZATION IN JAPANESE CHRONIC LYMPHOCYTIC LEUKEMIA: CLLRSG-01 STUDY.

    J. Takizawa, S. Aoki, R. Suzuki, N. Nakamura, K. Ohshima, K. Izutsu, A. Utsunomiya, J. Suzumiya

    HAEMATOLOGICA   100   678 - 678   2015.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • PNH型赤血球の出現を合併したEvans症候群の1例

    小林 弘典, 笠見 卓哉, 片桐 隆幸, 根本 洋樹, 河本 啓介, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 亀崎 豊実, 増子 正義

    臨床血液   56 ( 5 )   550 - 551   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Hodgkin-like ATLLの1症例

    鈴木 隆晴, 河本 啓介, 宮腰 淑子, 柴崎 康彦, 増子 正義, 曽根 博仁, 瀧澤 淳, 野本 信彦, 大島 孝一

    新潟医学会雑誌   129 ( 5 )   289 - 289   2015.5

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2015374716

  • 妊娠を契機に診断されたUpshaw-Schulman症候群症例における第二子妊娠の周産期管理

    森山 雅人, 玉木 悦子, 松本 雅則, 石西 綾美, 松本 吉史, 冨永 麻理恵, 工藤 理沙, 安達 聡介, 生野 寿史, 高桑 好一, 宮腰 淑子, 小堺 貴司, 小林 弘典, 牛木 隆志, 柴崎 康彦, 増子 正義, 瀧澤 淳, 成田 美和子, 曽根 博仁, 西條 康夫

    日本血栓止血学会誌   26 ( 2 )   193 - 193   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 白血病性形質細胞様樹状細胞株(PMDC11)およびPMDC11由来エクソソームを用いた抗原特異的細胞傷害性T細胞(CTL)の誘導

    内山 孝由, 成田 美和子, 岩谷 俊平, 大岩 恵理, 西澤 幹則, 高橋 益廣, 橋本 誠雄, 瀧澤 淳, 曽根 博仁, Kasahara Noriyuki

    新潟医学会雑誌   129 ( 3 )   125 - 139   2015.3

     More details

    Language:Japanese   Publisher:新潟医学会  

    私たちは白血病性形質細胞様樹状細胞株(PMDC05)を樹立し、この細胞株が抗原特異的細胞傷害性T細胞(CTL)誘導能を有することを報告してきた。さらに、CD80遺伝子を導入したPMDC05であるPMDC11の抗原提示能がさらに増強することも報告した。エクソソームは、多くの細胞により分泌される30〜100nmの大きさの小粒子であり、抗原提示細胞(APC)由来エクソソームは主要組織適合抗原(MHC)や抗原提示関連分子などを多く含んでいることが知られており、単球由来樹状細胞(moDC)の分泌するエクソソーム(dexosome)が抗原提示能を有することが示され、これを用いた臨床研究も行われている。本研究では、PMDC11細胞由来エクソソームを同定するとともに、PMDC11細胞とそのエクソソームによるCTL誘導について検討した。抗原ペプチドをパルスしたPMDC11細胞またはmoDCの培養上清からExoQuick-TCを用いてエクソソームを抽出した。この抽出物がエクソソームであることを、磁気ビーズとフローサイトメトリーを用いて確認した。磁気ビーズで捕捉した抽出物は、HLA-DR、CD54、CD86、CD80、CD123陽性であり、さらにエクソソームマーカーであるCD63(LAMP3)が陽性であることから、PMDC11細胞はエクソソーム(PMDC11-dex)を放出することが確認された。次に、サイトメガロウイルス(CMV)pp65ペプチドまたは改変型ウィルムス腫瘍遺伝子(mWT1)ペプチドをパルスしたPMDC11細胞を用いてHLA-A*24:02健常人末梢血CD8+T細胞を刺激培養し、抗原特異的CTL誘導についてテトラマー解析を行った。PMDC11細胞刺激培養において、抗原特異的CTLの増幅が確認された。CMV pp65ペプチドまたはmWT1ペプチドをパルスしたPMDC11細胞培養上清より抽出したPMDC11-dexによる刺激培養では、PMDC11-dex添加培養系において抗原特異的CTLの増幅が確認された。これらの結果よりPMDC細胞株はエクソソーム分泌能有し、PMDC11-dexは抗原特異的CTL誘導能を有することが示唆された。PMDC11細胞は、細胞自体がCTL養子免疫療法に応用できるのみならず、エクソソームを用いた無細胞系ワクチンの開発にも有用であると思われた。(著者抄録)

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://hdl.handle.net/10191/44037

  • 同種造血幹細胞移植における血清蛋白と発熱・炎症反応との関連性の検討

    森山雅人, 柴崎康彦, 増子正義, 根本洋樹, 片桐隆幸, 笠見卓哉, 河本啓介, 田中智之, 宮腰淑子, 小堺貴司, 小林弘典, 布施香子, 牛木隆志, 瀧澤淳, 曽根博仁, 西條康夫

    日本造血細胞移植学会総会プログラム・抄録集   37th   309   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • MDSに対する同種移植によるMDS transplant risk indexの有用性

    片桐隆幸, 柴崎康彦, 小林弘典, 牛木隆志, 佐藤直子, 矢野敏雄, 森山雅人, 黒羽高志, 瀧澤淳, 橋本誠雄, 小池正, 曽根博仁, 古川達雄, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   237   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 造血幹細胞移植後28日目の末梢血好酸球数50/μl未満は予後不良因子である

    河本啓介, 柴崎康彦, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   230   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 臍帯血移植後,血漿HHV‐6DNA量が比較的低値でありながらHHV‐6脳炎を発症したEBウイルス関連リンパ増殖症(EBV‐LPD)の一例

    根本洋樹, 小林弘典, 笠見卓哉, 片桐隆幸, 河本啓介, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 石原智彦, 西澤正豊

    日本造血細胞移植学会総会プログラム・抄録集   37th   306   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 重症再生不良性貧血に対する免疫抑制療法中に長期の潜伏期を経て発症したレジオネラ肺炎の1例

    小林 弘典, 宮腰 淑子, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 瀧澤 淳, 曽根 博仁, 田邊 嘉也

    臨床血液   55 ( 7 )   827 - 827   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • MALTリンパ腫65例の臨床病理学的検討

    瀧澤 淳, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 成田 美和子, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 青木 定夫, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   54   91 - 91   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • THE ASSOCIATION OF REDUCTION OF WT1 TRANSCRIPTS IN BONE MARROW AND OUTCOMES IN ACUTE MYELOID LEUKEMIA PATIENTS

    Y. Shibasaki, T. Tanaka, S. Miyakoshi, K. Fuse, T. Kozakai, H. Kobayashi, T. Ushiki, M. Moriyama, J. Takizawa, M. Narita, M. Takahashi, H. Sone, M. Masuko

    HAEMATOLOGICA   99   565 - 566   2014.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • 症候性多発性骨髄腫患者に対する自家末梢血幹細胞移植時の大量化学療法の有効性と安全性(JMSG-0901)

    松本 守生, 角南 一貴, 彼谷 裕康, 島崎 千尋, 黒田 純也, 瀧澤 淳, 五十嵐 忠彦, 村山 徹, 清水 一之, 吉田 喬

    International Journal of Myeloma   4 ( 2 )   50 - 50   2014.5

     More details

    Language:Japanese   Publisher:日本骨髄腫学会  

    researchmap

  • Long term generation of WT1 specific cytotoxic T lymphocytes in CML case treated with WT1 peptide vaccine

    Iwaya Shunpei, Narita Miwako, Masuko Masayoshi, Nishizawa Yoshinori, Ida Tori, Oiwa Eri, Iwabuchi Minami, Uchiyama Takayoshi, Shibazaki Yasuhiko, Takizawa Jun, Sone Hirohito, Takahashi Masuhiro

    新潟大学保健学雑誌 = Journal of health sciences of Niigata University   11 ( 1 )   83 - 91   2014.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    To clarify the effectiveness and safety of WT1 peptide vaccination against the residual CML cells, we started WT1 peptide vaccination in combination with regular dose of imatinib for a CML-CP patient who had been treated with 400 mg imatinib for 4 years but not achieved MMR. HLA-A*24:02-restricted mutant type WT1 peptide vaccination was undertaken 22 times totally. The appearance of WT1-specific CTLs in PB was confirmed by evaluating the frequency of MHC/WT1 tetramer+CD8+ T cells by using mixed lymphocyte peptide culture(MLPC)system every 4 weeks. WT1 tetramer+ cells detected by MLPC system were investigated for WT1 specific cytotoxicity. Bcr-abl transcripts have decreased to less than 500 copies by the administration of WT1 peptides every 4 weeks. After 7 months from the cessation of vaccination, transcripts decreased to the level of CMR, which is lasting thereafter Tumor antigen specific peptide vaccine therapy in combination with molecular targeted therapy is one of the potent methods for eradicating cancer stem cells.

    CiNii Article

    CiNii Books

    researchmap

  • 同種造血幹細胞移植における血清蛋白と発熱・炎症所見との関連性の検討

    松本瑛生, 森山雅人, 平安座依子, 田中智之, 宮腰淑子, 小堺貴司, 小林弘典, 布施香子, 柴崎康彦, 増子正義, 瀧澤淳, 古川達雄, 曽根博仁, 西條康夫

    日本造血細胞移植学会総会プログラム・抄録集   36th   360   2014.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • MYC転座陽性アグレッシブB細胞リンパ腫15例の後方視的解析

    瀧澤 淳, 宮腰 淑子, 田中 智之, 小堺 貴司, 小林 弘典, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁

    日本内科学会雑誌   103 ( Suppl. )   174 - 174   2014.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • Novel Prognostic Model Of Primary Mediastinal Large B-Cell Lymphoma (PMBL): A Multicenter Cooperative Retrospective Study In Japan

    Tomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, Chiaki Nakaseko, Hiroshi Arima, Kazuyuki Shimada, Makoto Sasaki, Jun Takizawa, Kinuko Mitani, Tadahiko Igarashi, Yoshinobu Maeda, Fumihiro Ishida, Nozomi Niitsu, Ken Ohmachi, Hirotaka Takasaki, Naoya Nakamura, Tomohiro Kinoshita, Shigeo Nakamura, Michinori Ogura

    BLOOD   122 ( 21 )   2013.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 多彩な画像所見を呈し肝生検で確診した血管内リンパ腫の1例

    眞水 麻以子, 西山 佑樹, 畠野 雄也, 阿部 寛幸, 上村 顕也, 高橋 祥史, 水野 研一, 竹内 学, 川合 弘一, 野本 実, 青柳 豊, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 石黒 敬信, 堅田 慎一, 西澤 正豊, 高野 徹

    新潟医学会雑誌   127 ( 10 )   581 - 582   2013.10

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014161062

  • 腹水を契機に発見されたTPLLの1例

    棚橋 怜生, 布施 香子, 田中 智之, 小堺 貴司, 森山 雅人, 増子 正義, 瀧澤 淳, 古川 達雄, 曽根 博仁

    新潟医学会雑誌   127 ( 7 )   386 - 386   2013.7

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014076248

  • 11 多彩な画像所見を呈し肝生検で診断しえた血管内リンパ腫の1例(一般演題, 第53回下越内科集談会)

    岩瀬 麻以子, 阿部 寛幸, 上村 顕也, 高橋 祥史, 水野 研一, 竹内 学, 川合 弘一, 野本 実, 青柳 豊, 畠野 雄也, 石黒 敬信, 堅田 慎一, 西澤 正豊, 岡塚 貴世志, 瀧澤 淳, 曽根 博仁, 高野 徹

    新潟医学会雑誌   127 ( 7 )   389 - 390   2013.7

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014076255

  • Nelarabine/Fludarabine併用療法により寛解を得たT-PLLの一例

    布施 香子, 瀧澤 淳, 宮腰 淑子, 田中 智之, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 三好 寛明, 大島 孝一, 横濱 章彦

    日本リンパ網内系学会会誌   53   151 - 151   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 妊娠を契機に診断された新規の遺伝子変異を伴うUpshaw-Schulman症候群(USS)の一例

    小堺 貴司, 森山 雅人, 布施 一郎, 柴崎 康彦, 増子 正義, 瀧澤 淳, 鳥羽 健, 吉田 邦彦, 小亀 浩市, 宮田 敏行, 松本 雅則, 藤村 吉博, 曽根 博仁

    日本血栓止血学会誌   24 ( 2 )   213 - 213   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 治療後3ヵ月の血清IL-2R値はびまん性大細胞型B細胞性リンパ腫の長期予後を反映する

    田中 智之, 瀧澤 淳, 宮腰 淑子, 小堺 貴司, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 尾山 徳秀, 大島 孝一

    日本リンパ網内系学会会誌   53   120 - 120   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 当科における悪性リンパ腫と合併する悪性腫瘍の後方視的検討

    宮腰 淑子, 瀧澤 淳, 田中 智之, 布施 香子, 小堺 貴司, 柴崎 康彦, 森山 雅人, 増子 正義, 曽根 博仁, 尾山 徳秀, 大島 孝一

    日本リンパ網内系学会会誌   53   113 - 113   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Disease Risk Index(DRI)が造血器腫瘍に対する同種造血幹細胞移植成績に与える影響

    田中智之, 増子正義, 小堺貴司, 布施香子, 柴崎康彦, 岡塚貴世志, 森山雅人, 宮腰淑子, 瀧澤淳, 鳥羽健, 曽根博仁, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   35th   212   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 腎移植後の腎障害合併MDS患者に対して減量フルダラビン,ブスルファンによる前処置による骨髄非破壊的造血幹細胞移植を行った一例

    西脇邦恵, 岡塚貴世志, 宮腰淑子, 柴崎康彦, 増子正義, 森山雅人, 瀧澤淳, 中川由紀, 斎藤和英, 鳴海福星, 高橋公太, 曽根博仁, 古川達雄

    日本造血細胞移植学会総会プログラム・抄録集   35th   265   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • A Mechanism For Acceleration Of Gm-Csf Autoantibody Production In Autoimmune Pulmonary Alveolar ProteINOSis

    K. Nakata, T. Nei, N. Motoi, S. Urano, R. Tazawa, K. Nakagaki, M. Suzuki, J. Takizawa

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   187   2013

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER THORACIC SOC  

    Web of Science

    researchmap

  • 11 著明な出血症状を呈した急性期特発性血小板減少性紫斑病に対しRomiplostimが奏功した1例(一般演題,第52回下越内科集談会)

    松尾 佑治, 岡塚 貴世志, 阿部 崇, 宮腰 淑子, 瀧澤 淳, 増子 正義, 古川 達雄, 鳥羽 健, 布施 一郎, 小玉 誠

    新潟医学会雑誌   126 ( 5 )   278 - 279   2012.5

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 急性GVHDがAML/MDSに対する同種造血幹細胞移植後後期の再発及び死亡に与える影響

    岡塚貴世志, 森山雅人, 増子正義, 瀧澤淳, 鳥羽健, 古川達雄

    日本内科学会雑誌   101   316   2012.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene.

    Yamahira A, Narita M, Ishii K, Jayathilake RM, Iwabuchi M, Satoh N, Uchiyama T, Taniguchi T, Hashimoto S, Kasahara N, Faure E, Bogan B, Takizawa J, Sone H, Takahashi M

    Leuk Res   36 ( 12 )   1541 - 6   2012

  • Gene Expression Profiling of Age-Related Epstein-Barr Virus (EBV)-Associated B-Cell Lymphoproliferative Disorder Uncovers Alterations in Immune and Inflammatory Genes: Possible Implications for Pathogenesis

    Harumi Kato, Kazuhito Yamamoto, Kennosuke Karube, Miyuki Katayama, Shinobu Tsuzuki, Yasushi Yatabe, Jun Takizawa, Koichi Ohshima, Shigeo Nakamura, Yasuo Morishima, Masao Seto

    BLOOD   118 ( 21 )   1474 - 1474   2011.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Hodgkin リンパ腫における血清IL‐2Rの意義

    宮腰淑子, 瀧澤淳, 田中智之, 布施香子, 東村益孝, 岡塚貴世志, 森山雅人, 増子正義, 古川達雄, 鳥羽健, 青木定夫, 中村直哉, 大島孝一

    臨床血液   52 ( 9 )   1188   2011.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 悪性リンパ腫WHO分類病型別の血清IL‐2R値

    田中智之, 瀧澤淳, 宮腰淑子, 布施香子, 東村益孝, 岡塚貴世志, 阿部崇, 森山雅人, 増子正義, 古川達雄, 鳥羽健, 青木定夫, 中村直哉, 大島孝一

    臨床血液   52 ( 9 )   1280   2011.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 加齢性EBV関連リンパ増殖性疾患の遺伝子発現解析

    加藤 春美, 山本 一仁, 加留部 謙之輔, 都築 忍, 谷田部 恭, 瀧澤 淳, 大島 孝一, 中村 栄男, 森島 泰雄, 瀬戸 加大

    臨床血液   52 ( 9 )   1120 - 1120   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 加齢性EBV関連B細胞性リンパ増殖性疾患の発現プロファイル(Gene expression profiling of EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly)

    加藤 春美, 山本 一仁, 加留部 謙之輔, 都築 忍, 谷田部 恭, 瀧澤 淳, 大島 孝一, 中村 栄男, 森島 泰雄, 瀬戸 加大

    日本癌学会総会記事   70回   443 - 443   2011.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 全身結節性皮疹で発症したtriple hit lymphomaの一例

    小堺貴司, 瀧澤淳, 北嶋俊樹, 東村益孝, 柴崎康彦, 阿部崇, 森山雅人, 増子正義, 古川達雄, 鳥羽健, 相澤義房, 木村芳三, 大島孝一

    日本リンパ網内系学会会誌   51   96   2011.6

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 皮膚に髄外病変を認めたinv(16)を有する急性骨髄性白血病の1例

    柴田怜, 柴崎康彦, 森山雅人, 滝澤淳, 増子正義, 古川達雄, 鳥羽健, 相澤義房

    新潟医学会雑誌   125 ( 5 )   291 - 291   2011.5

     More details

  • New chemotherapy for multiple myeloma

    Niigata medical journal   125 ( 2 )   61 - 64   2011.2

  • 発熱,好酸球増多,皮疹で発症した悪性リンパ腫の1例

    水澤健, 東村益孝, 百都亜矢子, 柴崎康彦, 森山雅人, 瀧澤淳, 鳥羽健, 青木定夫, 相澤義房

    新潟医学会雑誌   124 ( 6 )   350 - 351   2010.6

     More details

  • Occurrence Of IgA-/IgM-Type GM-CSF Autoantibody In The Sera Of Autoimmune PAP

    S. Urano, T. Nei, N. Motoi, C. Kaneko, J. Takizawa, R. Tazawa, B. Trapnell, K. Nakata

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   181   2010

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER THORACIC SOC  

    Web of Science

    researchmap

  • 免疫不全で発症したCD20陽性末梢性T細胞性リンパ腫の一例

    阿部崇, 西垣佑紀, 水澤健, 増子正義, 瀧澤淳, 青木定夫, 相澤義房, 中村直哉

    日本リンパ網内系学会会誌   50   2010

  • Mechanisms For Excessive Production Of GM-CSF Autoantibody In Autoimmune Pulmonary Alveolar Proteinosis

    T. Nei, S. Urano, C. Kaneko, N. Motoi, J. Takizawa, R. Tazawa, K. Nakagaki, K. Akagawa, B. Trapnell, K. Nakata

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   181   2010

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER THORACIC SOC  

    Web of Science

    researchmap

  • The Impact of Outcome and Hepatic Toxicity in HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis.

    Daisuke Ennishi, Yoshinobu Maeda, Nozomi Niitsu, Minoru Kojima, Koji Izutsu, Jun Takizawa, Shigeru Kusumoto, Masataka Okamoto, Masahiro Yokoyama, Yasushi Takamatsu, Kazutaka Sunami, Akira Miyata, Kayoko Murayama, Akira Sakai, Morio Matsumoto, Katsuji Shinagawa, Akinobu Takaki, Keitaro Matsuo, Tomohiro Kinoshita, Mitsune Tanimoto

    BLOOD   114 ( 22 )   1057 - 1057   2009.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 3 腫瘍随伴性天疱瘡を合併した濾胞性リンパ腫の1例(一般演題,第49回下越内科集談会)

    123 ( 7 )   374 - 374   2009.7

  • 同種造血幹細胞移植後の生着症候群による体液貯留に対するハンプ(カルペリチド)の有用性

    森山雅人, 柴崎康彦, 阿部崇, 矢野敏雄, 黒羽高志, 増子正義, 瀧澤淳, 鳥羽健, 古川達雄, 相澤義房

    日本内科学会雑誌   98   155   2009.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Sera from Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Promote the Differentiation of B Cells.

    T. Nei, H. Kanazawa, C. Kaneko, S. Urano, N. Motoi, A. Satoh, J. Takizawa, R. Tazawa, K. Nakagaki, K. S. Akagawa, B. C. Trapnell, K. Nakata

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   179   2009

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER THORACIC SOC  

    Web of Science

    researchmap

  • c‐myc遺伝子再構成を認めたCD5<sup>+</sup>CD10<sup>+</sup>DLBCLの2症例

    瀧澤淳, 中村直哉, 桃井明仁, 矢野敏雄, 森山雅人, 布施一郎, 中田光, 青木定夫, 相澤義房

    日本リンパ網内系学会会誌   48   75   2008.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 長期間左内頸CVカテーテル留置により発生し,右心房直上まで及んだ巨大血栓に対して大静脈フィルターを用い,救命し得た1例

    岡本竹司, 榛澤和彦, 佐藤浩一, 林純一, 瀧澤淳, 桃井明仁, 下田傑, 布施一郎

    新潟医学会雑誌   122 ( 5 )   2008

  • 5 再発治療抵抗性低悪性度B細胞リンパ腫に対するR-ClaM療法(Pilot Study)(I.一般演題,第49回新潟造血器腫瘍研究会)

    瀧澤 淳, 桃井 明仁, 東村 益孝, 倉崎 桃里, 矢野 敏雄, 阿部 崇, 八木沢 久美子, 鳥羽 健, 相澤 義房, 青木 定夫, 増子 正義, 古川 達雄, 関 義信, 橋本 誠雄, 小林 政

    新潟医学会雑誌   121 ( 12 )   718 - 718   2007.12

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2008162828

  • plasmacytoid DC leukemiaと考えられる2例の解析

    高橋英伸, 成田美和子, 橋本誠雄, 岡塚喜世志, 土山準二郎, 渡部紀宏, 杼木希, 斉藤杏里, 森山雅人, 倉崎桃里, 北嶋俊樹, 東村益孝, 桃井明仁, 矢野敏雄, 増子正義, 瀧澤淳, 青木定夫, 古川達雄, 鳥羽健, 高橋益廣, 相澤義房

    日本リンパ網内系学会会誌   47   107   2007.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • In vitro proliferation and anti-tumor cytotoxicity of γδT cells derived from PBMNC of patients with hematological malignancies

    Saitoh Anri, Narita Miwako, Watanabe Norihiro, Tochiki Nozomi, Takizawa Jun, Furukawa Tatsuo, Toba Ken, Aizawa Yoshifusa, Takahashi Masuhiro

    Bulletin of School of Health Sciences Faculty of Medicine Niigata University   8 ( 3 )   57 - 67   2007.3

     More details

    Language:Japanese   Publisher:Niigata University  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007221167

  • 2 Asian variant IVLの1例(第48回新潟造血器腫瘍研究会)

    柴崎 康彦, 瀧澤 淳, 矢野 敏雄, 増子 正義, 土山 準二郎, 青木 定夫, 鳥羽 健, 中村 直哉, 飯酒盃 訓充

    新潟医学会雑誌   121 ( 3 )   173 - 174   2007.3

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007306260

  • 当科におけるT細胞性リンパ腫の治療成績

    桃井 明仁, 瀧澤 淳, 牛木 隆志, 岡塚 貴世志, 狩俣 かおり, 矢野 敏雄, 増子 正義, 鳥羽 健, 青木 定夫, 相澤 義房

    日本内科学会雑誌   96 ( Suppl. )   158 - 158   2007.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • 5 CBA (Cytometric Beads Array)をもちいたサイトカインの網羅的測定法(第38回新潟血液同好会)

    東村 益孝, 塚田 信弘, 瀧澤 淳, 青木 定夫, 鳥羽 健, 相澤 義房

    新潟医学会雑誌   121 ( 2 )   121 - 122   2007.2

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007289014

  • BCL6 Rearrangement detected by FISH analysis is a poor prognostic factor in the "Non-Germinal center phenotype" of diffuse large B-Cell lymphoma.

    Jun Takizawa, Sadao Aoki, Akihito Momoi, Toshiki Kitajima, Masutaka Higashimura, Naoya Nakamura, Yoshifusa Aizawa

    BLOOD   108 ( 11 )   236B - 236B   2006.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • In vitro expansion of blood gamma delta T cells in patients with myeloma/lymphoma and anti-tumor cytotoxicity of the expanded gamma delta T cells.

    Anri Saito, Miwako Narita, Norihiro Watanabe, Nozorni Tochiki, Yumi Hiroi, Takayoshi Shirasaki, Jun Takizawa, Tatsuo Furukawa, Ken Toba, Sadao Aoki, Yoshifusa Aizawa, Masuhiro Takahashi

    BLOOD   108 ( 11 )   51B - 51B   2006.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 2 ホジキンリンパ腫化学療法後に発症した腸管気腫性嚢胞症の1例(第46回下越内科集談会)

    黒川 允, 阿部 崇, 堂森 浩二, 本間 圭一郎, 瀧澤 淳, 古川 達雄, 青木 定夫, 相澤 義房

    新潟医学会雑誌   120 ( 5 )   301 - 302   2006.5

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2006259545

  • Micafungin is extremely effective against fungal infections complicating hematological malignancies: Report of a multicenter study by N-FISH (Niigata Fungal Infection Study Group in Hematology).

    S Aoki, J Takizawa, Y Seki, K Takai, K Nikkuni, S Maruyama, N Nomoto, N Tsukada, Y Aizawa

    BLOOD   106 ( 11 )   423B - 423B   2005.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 高齢者の慢性リンパ性白血病と慢性骨髄性白血病

    瀧澤 淳, 青木定夫

    血液フロンティア   15 ( 9 )   1489 - 1498   2005.9

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher:医薬ジャーナル社  

    researchmap

  • 1 Trilineage leukemiaの4例(第47回新潟造血器腫瘍研究会)

    北嶋 俊樹, 柴崎 康彦, 矢野 敏雄, 増子 正義, 瀧澤 淳, 八木沢 久美子, 鳥羽 健, 相澤 義房, 橋本 誠雄, 古川 達雄

    新潟医学会雑誌   119 ( 6 )   370 - 371   2005.6

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2006006539

  • 1 免疫グロブリンJH鎖の再構成を認めたT-GLDPの1例(第46回新潟造血器腫瘍研究会)

    本間 圭一郎, 瀧澤 淳, 増子 正義, 鳥羽 健, 相澤 義房, 橋本 誠雄, 古川 達雄, 青木 定夫, 成田 美和子, 高橋 益廣, 中村 直哉

    新潟医学会雑誌   119 ( 5 )   316 - 317   2005.5

     More details

    Language:Japanese   Publisher:新潟大学  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2005231472

  • 骨髄破壊的造血幹細胞移植におけるBNPの推移

    増子 正義, 伊藤 正洋, 瀧澤 淳, 橋本 誠雄, 青木 定夫, 鳥羽 健, 小玉 誠, 古川 達雄, 相澤 義房

    日本内科学会雑誌   94 ( Suppl. )   163 - 163   2005.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • High-dose bi-weekly THP-COP induction treatment followed by high-dose therapy with autologous peripheral blood stem cell transplantation for advanced-stage follicular lymphoma as first-line therapy

    S Aoki, J Takizawa, M Higashimura, A Momoi, N Tsukada, K Nikkuni, N Nomoto, Y Aizawa

    BLOOD   104 ( 11 )   386B - 387B   2004.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 当科における血管内悪性リンパ腫4例の臨床的検討

    牛木 隆志, 塚田 信弘, 中村 直哉, 朝川 勝明, 阿部 崇, 黒羽 高志, 増子 正義, 瀧澤 淳, 八木沢 久美子, 橋本 誠雄, 鳥羽 健, 青木 定夫, 相澤 義房

    日本血液学会・日本臨床血液学会総会プログラム・抄録集   66回・46回   971 - 971   2004.9

     More details

    Language:Japanese   Publisher:日本臨床血液学会  

    researchmap

  • 骨髄再発後Tri-lineage phenotypeを示した同種幹細胞移植後再発Tリンパ芽球性リンパ腫

    森田 慎一, 増子 正義, 橋本 誠雄, 滝澤 淳, 本間 圭一郎, 青木 定夫, 古川 達雄, 鳥羽 健, 相澤 義房, 中村 直哉

    日本血液学会・日本臨床血液学会総会プログラム・抄録集   66回・46回   953 - 953   2004.9

     More details

    Language:Japanese   Publisher:日本臨床血液学会  

    researchmap

  • A pilot study of rituximab and high-dose bi-weekly THP-COP with G-CSF support (R-HDBWTCOP(G)) for low-grade non-Hodgkin's lymphoma.

    K Nikkuni, S Aoki, M Higashimura, A Momoi, N Tsukada, J Takizawa, K Takai, Y Aizawa

    BLOOD   102 ( 11 )   294B - 294B   2003.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Measurement of serum IL-10 and immunohistochemical staining of CD34 are useful for diagnosis of Asian variant of intravascular large B-cell lymphoma (AIVL).

    N Tsukada, T Abe, N Nakamura, A Momoi, J Takizawa, K Yagisawa, S Hashimoto, S Aoki, Y Aizawa

    BLOOD   102 ( 11 )   280B - 280B   2003.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 呼吸機能障害をきたした慢性骨髄単球性白血病急性転化例

    大瀧啓太, 橋本誠雄, 瀧沢淳, 塚田信弘, 森山雅人, 古川達雄, 鳥羽健, 相沢義房

    臨床血液   44 ( 8 )   756   2003.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ろ胞性リンパ腫に対する自家末梢血幹細胞移植併用大量化学療法の成績

    瀧沢淳, 青木定夫, 新国公司, 佐藤直子, 岡塚貴世志, 桃井明仁, 森山雅人, 塚田信弘, 相沢義房

    日本リンパ網内系学会会誌   43   55   2003.6

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • A phase II multicenter clinical trial of high-dose bi-weekly THP-COP with G-CSF support (HDBW-TCOP(G)) for non-Hodgkin's lymphoma.

    K Nikkuni, S Aoki, N Tsukada, J Takizawa, M Takahashi, K Takai, M Sanada, N Nomoto, Y Aizawa

    BLOOD   98 ( 11 )   136A - 136A   2001.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 3)同種骨髄移植後に, リンパ節で再発したCMLのTリンパ芽球性急性転化(I.一般演題, 第43回新潟造血器腫瘍研究会)

    岡塚 貴世志, 鳥羽 健, 青木 定夫, 新国 公司, 土山 準一郎, 瀧澤 淳, 相澤 義房, 河井 一浩, 永井 孝一, 鈴木 訓充

    新潟医学会雑誌   115 ( 9 )   481 - 481   2001.9

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2002137969

  • 3)慢性関節リウマチに合併した甲状腺原発悪性リンパ腫の一症例(I. 一般演題, 第66回膠原病研究会)

    瀧澤 淳, 鈴木 訓充, 樋口 渉, 青木 定夫, 相澤 義房

    新潟医学会雑誌   114 ( 1 )   31 - 31   2000.1

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2000171303

  • CD3, CD4, CD56 and CD57 positive chronic large granular T lymphocytosis.

    S Aoki, S Maruyama, N Nomoto, N Tsukada, J Takizawa, Y Osman, M Narita, M Takahashi, Y Aizawa

    BLOOD   92 ( 10 )   259B - 259B   1998.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:W B SAUNDERS CO  

    Web of Science

    researchmap

  • 薬剤起因性貧血

    瀧澤 淳

    別冊日本臨床 領域別症候群シリーズNo.20   413 - 415   1998.8

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher:日本臨床社  

    researchmap

  • 1)骨髄移植後, cytarabineによると思われる心タンポナーデをきたした1例(I. 一般演題, 第38回新潟造血器腫瘍研究会)

    湯浅 和久, 関 義信, 矢野 雅彦, 落合 幸江, 畔上 卓昭, 瀧澤 淳, 橋本 誠雄, 樋口 渉, 青木 定夫, 布施 一郎, 相澤 義房, 庭野 裕恵, 古川 達雄, 小池 正

    新潟医学会雑誌   112 ( 7 )   429 - 429   1998.7

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/1999100412

  • TCL1 Gene Expression in Hematopoietic Malignancies

    Jun TAKIZAWA

    Niigata medical journal   111 ( 9 )   547 - 555   1997.9

     More details

    Language:Japanese   Publisher:Niigata University  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/1998122075

  • Comparison of Long-term Survival Between Bone Marrow Transplanation and Maintenance Chemotherapy for Adult Acute Lymphoblastic Leukemia in First Remission

    SUZUKI Noriatsu, KOIKE Tadashi, FURUKAWA Tatsuo, NIWANO Hiroe, MARUYAMA Sohichi, NARITA Miwako, TAKIZAWA Jun, SATO Naoaki, HASHIMOTO Shigeo, NIKKUNI Koji, TOBA Ken, KISHI Kenji, TAKAHASHI Masuhiro, AIZAWA Yoshifusa, SHIBATA Akira

    38 ( 1 )   95 - 99   1997.1

  • 11q23転座領域遺伝子MLLの機能解析

    城 達郎, 鏡味 良豊, 瀬川 辰也, 瀧澤 淳, 上田 龍三, 瀬戸 加大

    日本分子生物学会年会プログラム・講演要旨集   19   712 - 712   1996.8

     More details

  • Autologous Bone Marrow Transplantation for Hematological MalignanciesSymposium Application of Autologous BMT to Cancer Treatment

    Takao GOTOH, Kenji KISHI, Jun TAKIZAWA

    Niigata medical journal   107 ( 9 )   802 - 807   1993.9

     More details

    Language:Japanese   Publisher:Niigata University  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/1994156607

▶ display all

Presentations

  • Prognosis of Chronic Lymphocytic Leukaemia in Japanese Patients: Results from the CLLRSG-01 Study.

    Jun Takizawa, Ritsuro Suzuki, Go Yamamoto, Toru Kiguchi, Atae Utsunomiya, Hideki Asaoku, Eiichi Ohtsuka, Kengo Takeuchi, Koji Izutsu, Naoya Nakamura, Koichi Ohshima, Sadao Aoki, Junji Suzumiya

    XIX iwCLL (International Workshop on CLL)  2021.9 

     More details

    Event date: 2021.9

    Language:English   Presentation type:Poster presentation  

    researchmap

  • リンパ腫治療が変わる?重要臨床試験の結果を読み解く 「慢性リンパ性白血病」 Invited

    瀧澤 淳

    日本リンパ網内系学会教育委員会主催 リンパ腫エキスパート養成セミナー2019  2019.11 

     More details

    Event date: 2019.11

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • Expression of LEF1 in Japanese cases of CLL (CLLRSG-01 study)

    Takizawa J, Suzuki R, Kawamoto K, Suzuki T, Kiguchi T, Masunari T, Utsunomiya A, Saburi Y, Murakami J, Kitazume K, Suzuki Y, Takeuchi K, Nakamura N, Ohshima, Aoki S, Suzumiya J

    XVIII iwCLL (International Workshop on CLL)  2019.9 

     More details

    Event date: 2019.9

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Characteristics of chronic lymphocytic leukemia in Japan (CLLRSG-01 study)

    Takizawa, J, Suzuki, R, Kiguchi, T, Izutsu, K, Asaoku, H, Saburi, Y, Masunari, T, Utsunomiya, A, Takeuchi, K, Nakamura, N, Ohshima, K, Aoki, S, Suzumiya, J

    XVII International Workshop on Chronic Lymphocytic Leukemia  2017.5 

     More details

    Event date: 2017.5

    Language:English   Presentation type:Poster presentation  

    researchmap

  • The characteristic of chronic lymphocytic leukemia in Japan: An interim result of CLLRSG-01 study

    Takizawa, J, Suzumiya, J, Suzuki, R, Kiguchi, T, Izutsu, K, Asaoku, H, Saburi, Y, Masunari, T, Utsunomiya, A, Nakamura, N, Ohshima, K, Aoki, S

    XVI International Workshop on Chronic Lymphocytic Leukemia  2015.9 

     More details

    Event date: 2015.9

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

Research Projects

  • 本邦CLLの病態解明に基づく簡便な新規診断法の確立

    Grant number:19K07863

    2019.4

    System name:科学研究費助成事業 基盤研究(C)

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    瀧澤 淳, 曽根 博仁, 大島 孝一, 河本 啓介

      More details

    Authorship:Principal investigator 

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    慢性リンパ性白血病(CLL)は西欧諸国で最も頻度の高い成人白血病であるが、本邦を含めた東アジアでは極めて希少な疾患で、その理由は不明のままである。その原因を解明するために本邦CLLの本態を明確にすることが本研究の目的である。2020年3月まで行ってきた国内前方視登録研究(CLLRSG-01)の登録症例を対象にして研究を行っている。
    登録症例に対してフローサイトメトリー(FCM)解析により免疫表現形を解析したが、免疫表現形が典型的(CD5陽性かつCD23陽性のB細胞腫瘍)なCLLと非典型的なCLL-like LPDに分類し、免疫組織化学(IHC)を用いてLEF1発現を検討した。Matutes score 4または5のCLL27例は全例LEF1陽性であったが、score 3のCLLは33例中LEF1陽性は20例(61%)のみで1/3以上がLEF1陰性であることが判明した。CLL-like LPDは21例中8例(38%)がLEF1陽性であり、これらが本当にCLLと異なる疾患であるか更なる検討が必要と考えられた。この検討結果は2019年9月に行われたinternational workshop on CLL (iwCLL2019)に採用され発表を行った。
    さらにCLL-like LPDの本態を明らかにするために濾胞辺縁帯B細胞に特徴的な分子と考えられるIRTA1とMNDAの発現についてIHCで検討を行った。陽性コントロールとして用いた濾胞辺縁帯B細胞由来リンパ腫(節性濾胞辺縁帯リンパ腫:NMZL、脾辺縁帯リンパ腫:SMZL、節外性脾辺縁帯MALT型リンパ腫)に発現が認められIHCが機能することが確認され、染色結果を集計している。現在、FISH解析による染色体異常や免疫グロブリン重鎖可変領域(IGHV)の体細胞突然変異(SHM)の有無を含め臨床的および細胞遺伝学的解析結果との比較検討を進めている。

    researchmap

  • CLL希少地域である日本からの挑戦~確実な鑑別診断法の確立と分子病態の解明~

    2016.4 - 2019.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    瀧澤 淳

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3600000 ( Direct Cost: \2520000 、 Indirect Cost:\1080000 )

    researchmap

  • IgG4関連疾患はMALTリンパ腫の発症原因になり得る

    2013.4 - 2017.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    瀧澤 淳, 尾山 徳秀

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\3800000 ( Direct Cost: \2660000 、 Indirect Cost:\1140000 )

    researchmap

  • 次世代シークエンサーを用いたGM-CSF自己抗体産生機序の解明

    2012.4 - 2015.3

    System name:科学研究費助成事業

    Research category:基盤研究(B)

    Awarding organization:日本学術振興会

    中田 光

      More details

    Grant type:Competitive

    researchmap

  • 特発生肺胞蛋白症における免疫変容の体系的研究

    2008.4 - 2011.3

    System name:科学研究費助成事業

    Research category:基盤研究(B)

    Awarding organization:日本学術振興会

    中田 光

      More details

    Grant type:Competitive

    researchmap

  • GM-CSF中和能の新規アッセイ法の確立

    2008.4 - 2010.3

    System name:科学研究費助成事業

    Research category:挑戦的萌芽研究

    Awarding organization:日本学術振興会

    中田 光

      More details

    Grant type:Competitive

    researchmap

  • 電磁波障害の無い細胞培養容器への個体認証用ICタグ装着法の開発

    2008.1 - 2008.3

    System name:科学技術振興機構(JST) 平成19年度 研究成果実用化検討(FS)課題

    Awarding organization:科学技術振興機構(JST)

      More details

    Grant type:Competitive

    Grant amount:\1000000 ( Direct Cost: \900000 、 Indirect Cost:\100000 )

    researchmap

▶ display all